US20140212892A1 - Method For Automated Tissue Analysis - Google Patents
Method For Automated Tissue Analysis Download PDFInfo
- Publication number
- US20140212892A1 US20140212892A1 US14/067,438 US201314067438A US2014212892A1 US 20140212892 A1 US20140212892 A1 US 20140212892A1 US 201314067438 A US201314067438 A US 201314067438A US 2014212892 A1 US2014212892 A1 US 2014212892A1
- Authority
- US
- United States
- Prior art keywords
- fluorescently labeled
- cellular systems
- systems biology
- data
- blood sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 114
- 238000004458 analytical method Methods 0.000 title description 53
- 230000001413 cellular effect Effects 0.000 claims abstract description 245
- 239000000090 biomarker Substances 0.000 claims abstract description 238
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 148
- 210000001519 tissue Anatomy 0.000 claims description 313
- 210000004027 cell Anatomy 0.000 claims description 154
- 206010028980 Neoplasm Diseases 0.000 claims description 152
- 201000011510 cancer Diseases 0.000 claims description 97
- 210000004369 blood Anatomy 0.000 claims description 89
- 239000008280 blood Substances 0.000 claims description 89
- 238000003384 imaging method Methods 0.000 claims description 67
- 210000005259 peripheral blood Anatomy 0.000 claims description 61
- 239000011886 peripheral blood Substances 0.000 claims description 61
- 210000002865 immune cell Anatomy 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 53
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 230000003287 optical effect Effects 0.000 claims description 39
- 230000001617 migratory effect Effects 0.000 claims description 29
- 230000004913 activation Effects 0.000 claims description 25
- 238000002372 labelling Methods 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 20
- 230000006907 apoptotic process Effects 0.000 claims description 15
- 210000001165 lymph node Anatomy 0.000 claims description 15
- 238000004393 prognosis Methods 0.000 claims description 15
- 238000003745 diagnosis Methods 0.000 claims description 13
- 210000005228 liver tissue Anatomy 0.000 claims description 13
- 230000026731 phosphorylation Effects 0.000 claims description 13
- 238000006366 phosphorylation reaction Methods 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 210000003463 organelle Anatomy 0.000 claims description 11
- 230000001988 toxicity Effects 0.000 claims description 11
- 231100000419 toxicity Toxicity 0.000 claims description 11
- 238000009826 distribution Methods 0.000 claims description 10
- 230000005778 DNA damage Effects 0.000 claims description 9
- 231100000277 DNA damage Toxicity 0.000 claims description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 6
- 230000017074 necrotic cell death Effects 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 claims description 5
- 210000004292 cytoskeleton Anatomy 0.000 claims description 5
- 102000020233 phosphotransferase Human genes 0.000 claims description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 230000019522 cellular metabolic process Effects 0.000 claims description 3
- 238000007621 cluster analysis Methods 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 claims description 2
- AXDJCCTWPBKUKL-UHFFFAOYSA-N 4-[(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]aniline;hydron;chloride Chemical compound Cl.C1=CC(=N)C(C)=CC1=C(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 AXDJCCTWPBKUKL-UHFFFAOYSA-N 0.000 claims description 2
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 claims description 2
- 229950003937 tolonium Drugs 0.000 claims description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 101
- 230000004044 response Effects 0.000 description 45
- 238000003556 assay Methods 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 32
- 238000002952 image-based readout Methods 0.000 description 29
- 230000006870 function Effects 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- 238000005259 measurement Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000013459 approach Methods 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 230000036755 cellular response Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 230000003915 cell function Effects 0.000 description 11
- 230000007170 pathology Effects 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 101150029707 ERBB2 gene Proteins 0.000 description 8
- 238000007876 drug discovery Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 231100000027 toxicology Toxicity 0.000 description 8
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 238000011223 gene expression profiling Methods 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 239000002679 microRNA Substances 0.000 description 7
- 230000004481 post-translational protein modification Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008827 biological function Effects 0.000 description 6
- 238000000423 cell based assay Methods 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 102000015694 estrogen receptors Human genes 0.000 description 6
- 108010038795 estrogen receptors Proteins 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 238000010191 image analysis Methods 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000033077 cellular process Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000000207 lymphocyte subset Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000006461 physiological response Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000005005 sentinel lymph node Anatomy 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- -1 Draq-5 Chemical compound 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical class C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000000339 bright-field microscopy Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 231100000613 environmental toxicology Toxicity 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 238000012921 fluorescence analysis Methods 0.000 description 3
- 238000001215 fluorescent labelling Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 210000004688 microtubule Anatomy 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000013425 morphometry Methods 0.000 description 3
- 230000007498 myristoylation Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000028617 response to DNA damage stimulus Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 231100000622 toxicogenomics Toxicity 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000035502 ADME Effects 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 101150071146 COX2 gene Proteins 0.000 description 2
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000009058 Death Domain Receptors Human genes 0.000 description 2
- 108010049207 Death Domain Receptors Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 102100034533 Histone H2AX Human genes 0.000 description 2
- 101710195517 Histone H2AX Proteins 0.000 description 2
- 102100033636 Histone H3.2 Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 231100000750 In vitro toxicology Toxicity 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 101150000187 PTGS2 gene Proteins 0.000 description 2
- 108010009711 Phalloidine Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000005183 environmental health Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007424 high content screening assay Methods 0.000 description 2
- 230000005931 immune cell recruitment Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002705 metabolomic analysis Methods 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 230000003562 morphometric effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 231100000683 possible toxicity Toxicity 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009211 stress pathway Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000000107 tumor biomarker Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- UBKVUFQGVWHZIR-UHFFFAOYSA-N 8-oxoguanine Chemical group O=C1NC(N)=NC2=NC(=O)N=C21 UBKVUFQGVWHZIR-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000692870 Inachis io Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005831 deiodination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010858 multiplexed labeling Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000009120 phenotypic response Effects 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000032029 positive regulation of DNA repair Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000016314 protein import into mitochondrial matrix Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1429—Signal processing
- G01N15/1433—Signal processing using image recognition
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
- G01N21/6458—Fluorescence microscopy
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10056—Microscopic image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/809—Multifield plates or multicontainer arrays
Definitions
- HCS High content screening
- multiparameter HCS technologies were developed to automate cell analysis for drug discovery, HCS technologies are focused specifically on the measurement of individual targets or pathways in arrays of cultured cells treated with test compounds.
- HCS tools alone do not address the complete workflow of tissue based cellular systems biology.
- the cell is the simplest living system. Tissues are collections of specific cell types forming interacting colonies of cells. Although cells and tissues are less complex than a complete organism, they possess significant functional complexity allowing a detailed understanding of many aspects affecting a whole organism, such as the cellular basis of disease, treatment efficacy and potential toxicity of treatments. Multicolor fluorescence of multiplexed biomarkers coupled with searchable databases provides the basis for cellular systems biology (also referred to herein as systems cell biology) profiling and analysis.
- This invention provides for methods of analyzing and profiling, the analysis of, and means for profiling, tissue-based cellular systems biology.
- the cellular systems biology approach including the combining of traditional histological staining with fluorescent staining to associate cellular and tissue markers that can be labeled by fluorescence has not been previously applied by others as now described herein.
- the use of the transmitted light images based on traditional histological stains used by pathologist as a “reference” image or “map” for better interpretation of the multiple fluorescence-based reagents as described herein will increase the acceptance of the systems approach by pathologists and will allow selection of a particular set of biomarkers for fluorescence analysis.
- cellular systems biology also referred to herein as systems cell biology
- systems cell biology is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions.
- a cellular systems biology profile is a systemic characterization of cells in the context of a tissue architecture such that the cells have particular characteristics dependent upon the relationships of different cells within a tissue and the biological or medical state of the tissue. It is the interactions, relationships, and state of the constituents of cells within a tissue that gives rise to the cellular systems biology features that are used to construct a profile.
- a cellular systems biology profile defines the interrelationships between a combination of at least five cellular systems biology features collected from cells within one or more tissue sections from the same sample.
- the invention is directed to a method for producing one or more cellular systems biology profiles for one or more tissue samples, comprising obtaining at least two sections from one or more tissue samples. At least one section is labeled with a histological stain, to produce a histologically stained section. At least one other section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. In some embodiments the histologically stained section and the fluorescently stained section are the same or different. In a particular embodiment, the histologically stained section and the fluorescently stained section are different section. Each fluorescently labeled reagent is specific for a biomarker.
- a “biomarker” is a molecule which provides a measure of cellular and/or tissue function.
- a biomarker can be the measure of estrogen receptor expression levels, Her2/neu expression, transcription factor activation, location or amount or activity of a protein, polynucleotide, organelle, and the like, the phosphorylation status of a protein, etc.
- the panel of fluorescently labeled reagents detects at least about four different biomarkers.
- a biomarker in one or more sections is a read-out of one or more features of the tissue.
- a “feature” is a characteristic which provides a measurement or series of measurements of a particular biomarker (which can indicate a biological function) made in time and/or space within cells and tissues.
- Bio functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non-coding RNAs and proteins, morphology, state of differentiation, and the like.
- a single biomarker can provide a read-out of more than one feature.
- Hoechst dye can be used to detect DNA (e.g., a biomarker), and a number of features of the tissue (e.g., nucleus size, cell cycle stage, number of nuclei, presence of apoptotic nuclei, etc.) can be identified by the DNA detected with the Hoechst dye.
- DNA e.g., a biomarker
- a number of features of the tissue e.g., nucleus size, cell cycle stage, number of nuclei, presence of apoptotic nuclei, etc.
- the method further comprises imaging the histologically stained section using a first optical mode, which produces a first set of data and imaging the fluorescently labeled section using a second optical mode, which produces a second set of data.
- the first set of data and the second set of data are analyzed to identify five or more features, such that at least one feature is identified in each of the first set of data and the second set of data.
- the combination of the five or more features generates a cellular systems biology profile of the one or more tissue samples.
- the cellular systems biology profile is stored in a database for reference, thereby providing a reference cellular systems biology profile in a database.
- the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples
- the method for producing a cellular systems biology profile of one or more tissue samples comprises obtaining at least one section from one or more tissue samples. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section, such that each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method further comprises imaging the fluorescently labeled section with at least a first optical mode to produce a first set of data which is analyzed to identify at least about five or more features, wherein at least one feature is identified in the first set of data, and wherein the combination of the five or more features is a cellular systems biology profile the one or more tissue samples.
- the method produces a cellular systems biology profile of the one or more tissue samples.
- the method can further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer.
- different cancers can be classified and staged according to their pathology.
- the method described herein permits, for example, the confirmation of the presence or absence of a cancer, the identification of a cancer, the classification of a cancer stage, the prediction and/or determination of the outcome or prognosis of the cancer, and the response of the cancer to any treatments.
- the method comprises obtaining at least two sections from one or more tissue samples.
- At least one section is labeled with a histological stain to produce a histologically stained section. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents comprises fluorescently labeled reagents which can be selected from the group consisting of: i) one or more fluorescently labeled reagents specific for at least four cancer cell biomarkers; ii) one or more fluorescently labeled reagents specific for at least four migratory immune cell biomarkers; iii) a combination of A) one or more fluorescently labeled reagents specific for at least three cancer cell biomarkers and B) one or more fluorescently labeled reagents specific for at least three migratory immune cell biomarkers, and iv) combinations of the above, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers.
- the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method further comprises imaging the histologically stained section with at least a first optical mode to produce a first set of data and imaging the fluorescently labeled section with at least a second optical mode to produce a second set of data.
- the first set of data and second set of data are analyzed to identify at least about five or more features, such that at least one feature is identified in each of the first set of data and the second set of data.
- the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples, and thus the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or the absence of a cancer.
- the one or more tissue samples is selected from the group consisting a suspected or known cancerous tissue, a lymph node, and a combination thereof.
- the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples
- a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
- the method comprises obtaining at least two sections from one or more tissue samples. At least one section labeled with a histological stain to produce a histologically stained section and at least one section is with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents comprises a set of fluorescently labeled reagents selected from the group consisting of i) one or more fluorescently labeled reagents specific for cell metabolism biomarkers, ii) one or more fluorescently labeled reagents specific for DNA damage biomarkers, iii) one or more fluorescently labeled reagents specific for cell morphology biomarkers, iv) one or more fluorescently labeled reagents specific for DNA damage biomarkers, v) one or more fluorescently labeled reagents specific for cell differentiation biomarkers, vi) one or more fluorescently labeled reagents specific for stress-induced transcription activation or inhibition biomarkers, vii) a one or more fluorescently labeled reagents specific for phosphorylation status of stress kinase biomarkers, viii) one or more fluorescently labeled reagents specific for apoptosis or necrosis biomarkers, ix) one or
- the histologically stained section is imaged with at least a first optical mode to produce a first set of data.
- the fluorescently labeled section is imaged with at least a second optical mode to produce a second set of data.
- the method further comprises analyzing the first set of data and second set of data to identify at least about five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data.
- the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples.
- the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
- the one or more tissue samples is one or more liver tissue samples.
- FIG. 1 are examples of slides for Tissue Profiling.
- FIG. 1A is Sample #01, which represents a slide that combines a tissue section labeled with H&E stain, and a sequential section labeled with fluorescent tags for specific biomarkers.
- FIG. 1B is Sample #02, which illustrates a slide with an H&E stained section, a fluorescent labeled section and some cells isolated from patient tissue and labeled with fluorescent tags (pictures of sections and cells are all enlarged for illustrative purposes).
- FIG. 2 is a schematic of systems cell biology (also referred to herein as cellular systems biology) profiling, which involves the analysis of a diverse set of cellular biomarkers used to identify features to create a profile.
- FIG. 2A represent cells from a patient that are, e.g., healthy, diseased or being treated or have been treated with a drug.
- FIG. 2B schematically represents the analysis of a set of biomarkers.
- FIG. 2C represents a panel of cellular biomarkers used to produce cellular systems biology profile.
- These profiles are stored in a database (schematically shown in FIG. 2D ), which can be used a reference database. Comparison of a patient profile with reference profiles is used e.g., as a predictive tool, or to associate a biomarker, feature or a profile with a specific medical condition, or to evaluate new profiles.
- FIG. 3 is a schematic illustrating the interrelation of systems cell biology which captures enough complexity to correlate biomarkers with higher level organ and organism effects, while allowing high throughput and cost-effective profiling.
- Cellular systems biology and systems biology are based on the interactions and relationships between the fundamental components of living systems represented by the “-omics” and a selection of specific cellular biomarkers are obtained from a combination of genomics, proteomics and metabolomics, in the context of the cells studied (cellomics).
- FIG. 4 is a schematic of how a cell integrates the many processes illustrated, such as gene expression, energy metabolism, etc. to yield normal functions. Diseases result from the dysregulation of one or more of these cellular processes which often results in complex symptoms. Many of these processes share pathways, signals and proteins and therefore should be investigated as part of the cell system (including the collection of cells of different types in tissues).
- FIG. 5 illustrate examples of biomarkers for use in patient tissue profiling selected from function classes that include, for example: (A) Stress Pathways; (B) Organelle Function; (C) Cell Cycle; (D) Morphology; (E) Apoptosis; and (F) DNA Damage, as well as micro RNA, and migratory immune cells. Specific combinations of biomarkers are selected for analysis of particular disease conditions, as described herein.
- FIG. 6 is an example of the multiplexed labeling of cells with a panel of biomarkers such as would be used in tissue sections. Labels are multiplexed in tissue which allows analysis of correlations between biomarker activation within the same tissue, and to reduce the number of sections that must be prepared and analyzed. In a particular embodiment, at least four or more biomarkers are analyzed in each section.
- FIG. 7 is a schematic flow chart of the process of creating a reference profile database as described in one embodiment of the invention.
- Box 1 Sequential tissue sections are prepared and mounted.
- Box 5 Data from the sequential sections are compared and combined.
- Box 6 The cellular systems profile is added to database.
- Box 7 Tissue profiles in database are clustered to identify similarities.
- Box 8 Profile classes are identified.
- Box 9 Correlations between systems profiles and histological data are used to build a classifier which is stored in the database.
- FIG. 8 is a flow chart illustrating the process of analyzing and classifying tissue, e.g., from a patient.
- FIGS. 9A-I is a flow chart illustrating the overall process for automated tissue profiling in one embodiment of the invention.
- FIG. 9(A) Process starts with reference tissue with know medical history.
- FIG. 9(B) Profiles from fluorescence analysis are combined with results from human interpretation of stained sections along with medical history;
- FIG. 9(C) to build a classifier and
- FIG. 9(D) populate a reference database.
- FIG. 9(E) Patient tissues are FIG. 9(F) prepared, analyzed and FIG. 9(G) classified to identify FIG. 9(H) similarities to other patient profiles (patient stratification) and FIG. 9(I) to make predictions regarding medical conditions, or medical outcomes.
- FIG. 10 is a flow chart of the process for selecting biomarkers for a cancer tissue profiling panel.
- Box ( 1 ) Normal tissue from Patient is (Box 2 ) analyzed by Gene Expression profiling.
- Box ( 3 ) A sample of tumor tissue from the same patient is (Box 4 ) analyzed by Gene Expression Profiling and is (Box 5 ) staged in the traditional manner. This combined information, comparing “normal” tissue with patient tumor tissue is (Box 6 ) used to identify potential biomarkers.
- Box ( 7 ) Gene products are prioritized based on known reference points including Her2/Neu and then antibodies acquired or produced to create test panels (Box 8 ). The design of the biomarker panel is based on the selection of combinations of cancer cell biomarkers that are multiplexed for fluorescence-based immunohistochemistry (IHC).
- IHC fluorescence-based immunohistochemistry
- FIG. 11 is an overview of one embodiment of the invention.
- Tissue samples from a patient which could include healthy tissue, tumor tissue, other diseased tissue or a blood specimen are processed by standard methods for mounting on slides (B) either as individual sections or as tissue microarrays. Slides are imaged on a microscope or other imaging system (C). Images are interpreted either by a pathologist or through the application of image analysis algorithms to produce data (D) which can be stored in a database. The combination of the data from a single specimen forms a cellular systems profile of that specimen.
- Data from multiple cellular systems profiles are analyzed using statistical methods including cluster analysis, principle component analysis, and other multifactorial methods to identify similarities between profiles which can be represented in a clustered heat map (E), identify patterns within a profile that indicate a certain biological or medical state, and to classify tissue status based on similarity in profiles.
- the information provided by cellular systems biology profiling is used by the physician or scientist (F) to better understand the biology or progression of a disease or biological condition, to more precisely stratify patients in a clinical trial and/or to optimize a therapeutic approach (G) to treating a condition.
- Cellular systems biology is defined as the investigation of the integrated and interacting networks of genes, proteins, and metabolic reactions that give rise to function and life.
- Cells in tissues, as complex systems exhibit properties that are not anticipated from the analysis of individual components, known as emergent properties that require analysis of many factors to characterize cellular states.
- Taylor and Giuliano [10] describe the application of in vitro cell systems analysis to drug discovery. In this analysis, correlation between measurements in individual cells was required to identify and interpret cell responses to drug treatment.
- Cellular systems biology features are defined as a data measurements or a series of measurements of a particular biological function (typically evidenced by the presence, absence and/or level of one or more biomarkers) made in time and/or space within cells and tissues.
- biological functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non-coding RNAs and proteins.
- HCS High Content Screening
- HCS image analysis tools can also be used to extract data from cells in tissues as part of a cellular systems biology profiling approach that would enable the characterization of complex and emergent properties that arise in living cells and tissue.
- image analysis software packages including those that are supplied with microscope slide scanning systems could be applied to extract cellular features from images of tissues to build a cellular systems biology profile.
- Cellular systems biology profiles are defined as the interrelationships between combination of at least about five cellular systems biology features collected from cells within one or more tissue sections from the same sample. These interrelationships are calculated either arithmetically (e.g., ratios, sums, or differences between cellular systems biology feature values) or statistically (e.g., hierarchical clustering methods or principal component analyses of combinations of cellular systems biology feature values). Cellular systems biology profiles can be used to understand the complex response of cells and tissues to disease and various treatments by characterizing the emergent properties of the cellular systems response.
- “Emergent properties” refers to the arising of novel and coherent structures, patterns, and properties during the process of self-organization in complex systems (Goldstein, Jeffrey (1999), “Emergence as a Construct: History and Issues”, Emergence: Complexity and Organization 1: 49-72).
- the emergent properties of cells and tissues e.g., growth and division, transformation to a tumor phenotype, etc.
- Emergent properties are not anticipated from the analysis of individual components, but require analysis of many factors to characterize cellular states.
- tissue sections have value
- the application of a “systems approach” wherein, as provided herein, multiple features (e.g., at least about four features, at least about five features, at least about six features, at least about 7-12 features, or more), of a tissue are analyzed enables a more precise determination of the state of the cells, the tissues, and the organism as a whole.
- this approach facilitates, for example, the automation of tissue analysis, and the production of tissue profiles for more precise tumor staging, personalized treatments, evaluation of treatment efficacy, and early indication of side effects, as well as improved analyses in animal toxicology studies in drug discovery.
- Tissues are collections of specific cell types forming interacting colonies of cells. Although cells and tissues are less complex than a complete organism, they possess significant functional complexity allowing a detailed understanding of the cellular basis of disease, treatment efficacy and potential toxicity of treatments. Multicolor fluorescence of multiplexed biomarkers coupled with searchable databases provides the basis for systems cell analysis.
- cellular systems biology also referred to herein as systems cell biology
- systems cell biology is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions.
- a cellular systems biology profile is a systemic characterization of cells in the context of a tissue architecture such that the cells have particular characteristics dependent upon the relationships of different cells within a tissue and the biological or medical state of the tissue. It is the interactions, relationships, and state of the constituents of cells within a tissue that gives rise to the cellular systems biology features that are used to construct a profile.
- a cellular systems biology profile defines the interrelationships between a combination of at least about five cellular systems biology features collected from cells within one or more tissue sections from the same sample.
- a cellular systems biology profile is the combination of at least about six, seven, eight, nine, ten, eleven, twelve, or more features.
- the method comprises obtaining at least two sections from one or more tissue samples.
- tissue sample can be epithelium, muscle, organ tissue, nerve tissue, tumor tissue, and combinations thereof.
- blood is not a tissue sample.
- Samples of tissue can be obtained by any standard means (e.g., biopsy, core puncture, dissection, and the like, as will be appreciated by a person of skill in the art). At least one section is labeled with a histological stain, to produce a histologically stained section.
- histological stains can be any standard stain as appreciated in the art, including but not limited to, alcian blue, Fuchsin, haematoxylin and eosin (H&E), Masson trichrome, toluidine blue, Wright's/Giemsa stain, and combinations thereof.
- traditional histological stains are not fluorescent. At least one other section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section.
- the panel of fluorescently labeled reagents comprises a number of reagents, such as fluorescently labeled antibodies, fluorescently labeled peptides, fluorescently labeled polypeptides, fluorescently labeled aptamers, fluorescently labeled oligonucleotides (e.g. nucleic acid probes, DNA, RNA, cDNA, PNA, and the like), fluorescently labeled chemicals and fluorescent chemicals (e.g., Hoechst 33342, propidium iodide, Draq-5, Nile Red, fluorescently labeled phalloidin), and combinations thereof.
- Each fluorescently labeled reagent is specific for at least one biomarker.
- a “biomarker” is a molecule which provides a measure of cellular and/or tissue function.
- a biomarker can be the measure of receptor expression levels, (e.g., estrogen receptor expression levels, Her2/neu expression); transcription factor activation; location or amount or activity of a protein, polynucleotide, organelle, and the like; the phosphorylation status of a protein, etc.
- a biomarker is a nucleic acid (e.g., DNA, RNA, including micro RNAs, snRNAs, mRNA, rRNA, etc.), a receptor, a cell membrane antigen, an intracellular antigen, and extracellular antigen, a signaling molecule, a protein, and the like.
- the panel of fluorescently labeled reagents detects at least about four different biomarkers.
- the panel of fluorescently labeled reagents detects at least about four to about six, to about ten, to about twelve different biomarkers or more.
- the panel of fluorescently labeled reagents detects at least about three different biomarkers.
- each fluorescently labeled reagent has different fluorescent properties, which are sufficient to distinguish the different fluorescently labeled reagents in the panel.
- a biomarker in one or more sections is a read-out of one or more features of a cellular systems biology profile.
- a “feature” is a characteristic which provides a measurement or series of measurements of a particular biomarker (which can indicate a biological function) made in time and/or space within cells and tissues.
- Bio functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non-coding RNAs and proteins, morphology, state of differentiation, and the like.
- a single biomarker can provide a read-out of more than one feature.
- Hoechst dye detects DNA, which is an example of a biomarker.
- a number of features can be identified by the Hoechst dye in the tissue sample such as nucleus size, cell cycle stage, number of nuclei, presence of apoptotic nuclei, etc.
- the method further comprises imaging the histologically stained section using a first optical mode, which produces a first set of data and imaging the fluorescently labeled section using a second optical mode, which produces a second set of data.
- the optical mode for imaging can be any mode suitable for this use, e.g., transmitted light microscopy, fluorescence light microscopy, wide field microscopy, confocal microscopy, and combinations thereof, as appropriate.
- the data produced in either or both of the first set of data and second set of data can be digital data.
- the first set of data and the second set of data are analyzed to identify five or more features, such that at least one feature is identified in the first set of data and at least one feature is identified in the second set of data.
- the combination of the five or more features generates a cellular systems biology profile of the one or more tissue samples.
- the imaging procedures are automated. Furthermore, analyzing the data can be performed manually, by automation or a combination thereof. As will be appreciated by a person of skill in the art, imaging a histologically stained section and imaging a fluorescently labeled section can be done sequentially or simultaneously. In addition, histological labeling and fluorescent labeling can be done sequentially or simultaneously. In some embodiments, after obtaining one or more sections from a tissue sample, the method is wholly automated.
- the method further comprises comparing the cellular systems biology profiles of two or more tissue samples in order to identify similarities, differences, or combinations thereof, of the two or more tissue samples.
- the two or more tissue samples are serial sections from a single tissue specimen.
- Serial sections of a single tissue sample are tissue sections which were adjacent to each other in the preparation of two or more sections from a tissue sample.
- the one or more tissue samples are isolated from one or more animals.
- the one or more animals are one or more humans.
- one or more tissue samples are isolated from a human patient at one or more time points, such that at least one tissue sample is isolated from each time point from the same patient.
- the panel of fluorescently labeled reagents indicate the presence, amount, location, activity, distribution, or combination thereof, of the biomarkers in the fluorescently labeled section.
- the location of a biomarker can be intracellular, extracellular, within specific intracellular locations, at specific extracellular locations, and combinations thereof.
- Activity of a biomarker can be the activation state of the biomarker (such as indicated, e.g., by its phosphorylation state, conformation state, or intracellular location, and the like).
- the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one blood sample obtained from the same source as the one or more tissue samples.
- the blood sample is a peripheral blood sample.
- Peripheral blood is the cellular components of blood, consisting of red blood cells, white blood cells, and platelets, which are found within the circulating pool of blood and not sequestered within the lymphatic system, spleen, liver, or bone marrow.
- the method comprises obtaining at least one blood sample smear from at least one peripheral blood sample from the same source as the one or more tissue samples.
- peripheral blood samples can be obtained by any standard procedure.
- the at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents detects at least about four different biomarkers.
- the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method further comprises imaging the fluorescently labeled blood sample smear with at least a third optical mode, such that the imaging produces a third set of data.
- the third set of data is analyzed to identify at least about five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear.
- This method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- the at least one peripheral blood sample is taken at the same or different time point as the one or more tissue samples are obtained.
- more than one peripheral blood sample is taken at different time points, and the cellular systems biology profiles of the more than one peripheral blood samples are compared.
- the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of one or more peripheral blood samples obtained from the same source as the one or more tissue samples.
- the method comprises obtaining at least two blood sample smears from one or more peripheral blood samples. At least one blood sample smear is labeled with a histological stain to produce a histologically stained blood sample smear. In addition, at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear.
- Each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least about four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the histologically stained blood sample smear is imaged with at least a third optical mode to produce a third set of data.
- the fluorescently labeled blood sample smear is imaged with at least a fourth optical mode to produce a fourth set of data.
- the third set of data and the fourth set of data are analyzed to identify at least about five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, such that the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears.
- the method produces a cellular systems biology profile of the one or more peripheral blood samples obtained from the same source as the one or more tissue samples.
- the one or more peripheral blood samples are taken at the same or different time point as the one or more tissue samples are obtained.
- the cellular systems biology profiles of the one or more peripheral blood samples are compared.
- a method for producing a cellular systems biology profile of one or more tissue samples comprises obtaining at least one section from one or more tissue samples. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section, such that each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method further comprises imaging the fluorescently labeled section with at least a first optical mode to produce a first set of data which is analyzed to identify at least about five or more features, wherein at least one feature is identified in the first set of data, and wherein the combination of the five or more features is a cellular systems biology profile the one or more tissue samples.
- the method produces a cellular systems biology profile of the one or more tissue samples.
- the method further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- the method comprises obtaining at least one blood sample smear from at least one peripheral blood sample.
- the at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, such that each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method further comprises imaging the fluorescently labeled blood sample smear with at least a second optical mode to produce a second set of data.
- the second set of data is analyzed to identify at least about five or more features, such that the five or more features is a cellular systems biology profile of the at least one blood sample smear.
- the method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- the method further comprises labeling at least one blood sample smear with a histological stain to produce a histologically stained blood sample smear.
- the histologically stained blood sample smear is imaged to produce an additional set of data which is analyzed to identify at least one feature, wherein the combination of the five or more features identified in the combination of the histologically stained blood sample smear and the fluorescently stained blood sample smear is a cellular systems biology profile of the one or more blood sample smears.
- a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer.
- different cancers can be classified and staged according to their pathology.
- the method described herein permits, for example, the confirmation of the presence or absence of a cancer, the identification of a cancer, the classification of a cancer stage, the prediction and/or determination of the outcome or prognosis of the cancer, and the response of the cancer to any treatments.
- the method comprises obtaining at least two sections from one or more tissue samples.
- At least one section is labeled with a histological stain to produce a histologically stained section. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents comprises fluorescently labeled reagents which can be selected from the group consisting of: i) a set of fluorescently labeled reagents specific for at least four cancer cell biomarkers; ii) a set of fluorescently labeled reagents specific for at least four migratory immune cell biomarkers; iii) a combination of A) a set of fluorescently labeled reagents specific for at least three cancer cell biomarkers and B) a set of fluorescently labeled reagents specific for at least three migratory immune cell biomarkers, and iv) combinations of the above, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers.
- the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method further comprises imaging the histologically stained section with at least a first optical mode to produce a first set of data and imaging the fluorescently labeled section with at least a second optical mode to produce a second set of data.
- the first set of data and second set of data are analyzed to identify at least about five or more features, such that at least one feature is identified in each of the first set of data and the second set of data.
- the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples, and thus the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or the absence of a cancer.
- the cancer is breast cancer.
- the fluorescently labeled reagents specific for cancer cell biomarkers detect cancer cell markers such as HER2/neu, estrogen receptor (ER), Ki-67, Cox-2, p16 and the like.
- the fluorescently labeled reagents specific for migratory immune cell biomarkers detect migratory immune cell biomarkers such as NK cell biomarkers, LAK cell biomarkers, TRAIL, PD1, biomarkers of immune cell apoptosis, and the like.
- a feature is a ratio of different migratory immune cell subtypes as detected by the migratory immune cell biomarkers, such that the ratio is indicative of the presence of a cancer, the stage of cancer, the diagnosis of a cancer, the prognosis of a cancer, the absence of a cancer and combinations thereof.
- the one or more tissue samples is selected from the group consisting a suspected or known cancerous tissue, a lymph node, and a combination thereof.
- Migratory immune cells are typically white blood cells (leukocytes).
- examples of migratory immune cell biomarkers include, without limitation, the percentage and ratios of specific migratory immune cells in tumors, tumor draining lymph nodes, non-sentinel lymph nodes and peripheral blood.
- Examples of migratory immune cells in normal blood include: (1) lymphocytes (25% of white blood cells) which includes T-cells (distinct sub-types), B-cells (distinct sub-types), and natural killer (NK) cells; (2) Neutrophils (65% of white blood cells); (3) Eosinophils (4% of white blood cells) and (4) Monocytes (6% of white blood cells), which includes macrophages (distinct sub-types).
- the percentage ranges of immune cells in tissues for cellular systems biology profiling comprise one or more of the following: lymphocytes from about 1% to about 90% (with distinct sub-types within this percentage, as will be recognized by a person of skill in the art); neutrophils from about 1% to about 90%; eosinophils from about 0.01% to about 50%; monocytes from about 0.01% to about 50% (with distinct sub-types within this percentage, as will be recognized by a person of skill in the art).
- the ranges of ratios of immune cells in tissues for cellular systems biology profiling comprise one or more of the following: T-cell lymphocytes/B-cell lymphocytes from about 0.1 to about 1000; dendritic cells/lymphocytes from about 0.01 to about 1000; macrophages/lymphocytes from about 0.01 to about 1000; lymphocyte sub-set/lymphocyte sub-set from about 0.01 to about 1000.
- the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- the method comprises obtaining at least one blood sample smear from at least one peripheral blood sample and labeling the at least one blood sample smear with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear.
- Each fluorescently labeled reagent is specific for a biomarker, and the panel of fluorescently labeled reagents detects at least about four different biomarkers.
- the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method further comprises imaging the fluorescently labeled blood sample smear with at least a third optical mode to produce a third set of data.
- the third set of data is analyzed to identify five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear.
- the method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- the at least one peripheral blood sample is taken at the same or different time point as the one or more tissue samples are obtained. In another embodiment, more than one peripheral blood sample is taken at different time points, and the cellular systems biology profiles of the more than one peripheral blood samples are compared.
- the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- the method comprises obtaining at least two blood sample smears from one or more peripheral blood samples and labeling at least one blood sample smear with a histological stain to produce a histologically stained blood sample smear.
- the method further comprises labeling at least one blood sample smear with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, such that each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile.
- the method also comprises imaging the histologically stained blood sample smear with at least a third optical mode to produce a third set of data and imaging the fluorescently labeled blood sample smear with at least a fourth optical mode to produce a fourth set of data.
- the third set of data and the fourth set of data are analyzed to identify at least about five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, such that the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears.
- the method produces a cellular systems biology profile of one the or more peripheral blood samples obtained from the same source as the one or more tissue samples, wherein the tissue sample is profiled for the presence or absence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer of the absence of a cancer.
- the one or more peripheral blood samples are taken at the same or different time points as the one or more tissue samples are obtained.
- more than one peripheral blood samples are taken at different time points, and the cellular systems biology profile of the more than one peripheral blood samples are compared.
- a method for producing a cellular systems biology profile of one or more tissue samples wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
- the method comprises obtaining at least two sections from one or more tissue samples. At least one section labeled with a histological stain to produce a histologically stained section and at least one section is with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker.
- the panel of fluorescently labeled reagents comprises a set of fluorescently labeled reagents selected from the group consisting of i) a set of fluorescently labeled reagents specific for cell metabolism biomarkers, ii) a set of fluorescently labeled reagents specific for DNA damage biomarkers, iii) a set of fluorescently labeled reagents specific for cell morphology biomarkers, iv) a set of fluorescently labeled reagents specific for DNA damage biomarkers, v) a set of fluorescently labeled reagents specific for cell differentiation biomarkers, vi) a set of fluorescently labeled reagents specific for stress-induced transcription activation or inhibition biomarkers, vii) a set of fluorescently labeled reagents specific for phosphorylation status of stress kinase biomarkers, viii) a set of fluorescently labeled reagents specific for apoptosis or necrosis biomarkers
- the histologically stained section is imaged with at least a first optical mode to produce a first set of data.
- the fluorescently labeled section is imaged with at least a second optical mode to produce a second set of data.
- the method further comprises analyzing the first set of data and second set of data to identify at least about five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data.
- the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples.
- the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
- the one or more tissue samples is one or more liver tissue samples.
- Staining and Transmitted Light Imaging in Pathology, Toxicology and Personalized Medicine Standard histological methods for staining and imaging of tissue sections in Pathology, and Toxicology were developed to meet the needs of pathologists and toxicologists to view the sections and make a determination based on experience and knowledge. Stains such as H&E (Hematoxylin and Eosin), congo red, Gram bacterial stain and others provide the means to label various cell types and structures, to facilitate interpretation. Although experienced pathologists can learn to interpret the staining patterns, efforts to automate the interpretation of the patterns have met with great difficulty.
- H&E Hematoxylin and Eosin
- Fluorescent labeling technologies allow for very specific labeling of cellular components, high signal to background, the ability to distinguish multiple labels on a single specimen, and the ability to detect comparatively small numbers of targets in each cell. While these properties make fluorescence nearly ideal for automated imaging, the use of fluorescence in visual interpretation is more limited due to bleaching, limited spectral response of the eye, and the limited dynamic range of the eye. Efforts to automate pathology have principally been guided by the staining and interpretation methods used by the pathologist.
- Drug Discovery On average, pharmaceutical companies spend more than $1 billion to bring a new drug to market, yet despite this large investment of time and resources, the frequency of drug failure is high. Poor efficacy and drug induced toxicity continue to be major causes of these failures [11, 12]. Furthermore, many candidate drugs fail late, in animal testing or clinical testing, after significant investment in development. Clearly, improved methods of functional assessment are needed in drug discovery, as well as in other fields such as environmental health and industrial safety. Efficacy and toxicity studies are carried out at several points during drug development including cell-based assays, ADME animal studies and clinical trials. Improvements in the reliability of tissue analysis are expected to improve the reliability and safety of drug testing.
- Genomics and proteomics have laid the groundwork for diagnostic and therapeutic treatments that are customized for each individual patient. This personalized medicine is based on a systems approach to disease which takes into account a profile of the whole patient, to determine the most effective therapy [2].
- the molecular information derived from genomics and proteomics, and in particular those genes and proteins that have been correlated with particular disease conditions, often referred to as biomarkers, is certainly a valuable source of patient data, but the customization of the treatments will still be limited to well characterized classes of biomarkers, since therapies cannot be tested for every individual genome.
- Environmental Toxicology The challenge in environmental toxicology is to assess the impact of a growing list of natural and man-made substances on human health. Several factors complicate the problem: increasing large numbers of substances must be tested; the complexities of environmental exposure require testing over a broad range of exposure mechanism, concentration and time; and uncertainties regarding the influence of age and genetic variability on the results. Reliable means to improve the efficiency of testing and evaluation are actively being sought by the National Toxicology Program at the National Institutes of Health.
- Biomedical research Cell analysis is routinely used in basic biological research as well as in medical research. In both cases the cell analysis is usually focused on a single cellular process, as there are limited tools available for analyzing complex, multi-component system responses.
- In vivo toxicology measures acute and chronic toxicity in several areas including mutagenicity, organ cytotoxicity, immunotoxicity, neurotoxicity, teratogenicity, and safety pharmacology.
- In vitro toxicology assays such as CYP450 induction, Ames test, MTT assay and others, are used to measure these functional responses.
- In vitro toxicology assays are typically cell based assays which use a variety of cell types including hepatocytes, cardiomyocytes, and others.
- Toxicogenomics uses a combination of traditional genetics and toxicology to identify patterns of gene expression that are associated with toxic effects. Toxicogenomics profiles typically include information such as nucleotide sequences, gene expression levels, protein synthesis, protein function and some phenotypic responses. One goal of toxicogenomics is to identify a sequence of genomic events that lead to a toxic biological response. [13].
- Cell-Based Assays of Cytotoxicity are designed to detect a specific endpoint in a population of cells. Examples include trypan blue staining, in which cell death is assessed microscopically by measuring the uptake of trypan blue dye that is excluded by live cells. Other vital stains and fluorescent DNA-binding dyes which are also excluded from live cells can also be used. In another assay format, live cells are labeled with a probe which is released upon cell death. Toxicity can also be assessed by measuring specific cellular functions. One of the more common assays is the MTT assay, where cell proliferation is measured by the activity of a mitochondrial enzyme. Other assays measure specific cellular markers.
- Examples include measurement of the activation of markers associated with the inflammation such as PGE-2, TNF ⁇ , IL1b and other interleukins.
- Assay formats can be in live cells, fixed cells or cell extracts. Many of the same biomarkers used in these assays will be useful as components of a panel of tissue based cellular biomarkers.
- Metabolism Drug effect on metabolism is measured by radioactive precursor uptake, thymidine, uridine (or uracil for bacteria), and amino acid, into DNA, RNA and proteins. Carbohydrate or lipid synthesis is similarly measured using suitable precursors. Turnover of nucleic acid or protein, or the degradation of specific cell components, is measured by prelabeling (or pulse labeling) followed by a purification step and quantitation of remaining label or sometimes by measurement of chemical amounts of the component. Energy source metabolism is also analyzed for optimal cell growth.
- Light microscopy shows the general state of cells, and combined with trypan blue exclusion, the percent of viable cells. Small, optically dense cells indicate necrosis, while bloated “blasting” cells with blebs indicate apoptosis. Phase microscopy views cells in indirect light; the reflected light shows more detail, particularly intracellular structures. Fluorescence microscopy detects individual components in cells, after labeling with selective dyes or specific antibodies, and can be used to identify cellular features associated with metabolic states.
- High Content Screening was developed as a method whereby one or more cellular features are measured and analyzed in arrays of cells to identify a cellular functional response [5, 14, 15].
- an HCS assay might be used to measure the activation of a particular receptor [16], mitochondrial activity [17], the onset of apoptosis [5, 18], or another cellular function.
- Each of these cellular features represents a measurement of particular cellular component.
- a single cellular feature is sufficient to indicate a single cellular function or response.
- the measurement of several features is required to specifically indicate a cellular response.
- a commercial apoptosis assay uses four cell features to more specifically indicate apoptosis. These features are interpreted based on the knowledge of the biology of apoptosis.
- Multiparameter cytotoxicity assays have been developed by nearly all vendors of HCS technologies. These assays are typically two to four parameter assays which measure cellular features related to cell death, either by necrosis or apoptosis. These assays have been applied in drug discovery, and testing for environmental agents of biowarfare [19] on cultured cells and primary cell preparations. Many of the biomarkers used in HCS can also be used in combinations as components of a feature vector of cellular states in tissue sections and other tissue specimens.
- Reagent Technologies Multiple reagent technologies are available to assay cellular functions. Fluorescent reagent technologies have matured over the last two decades, with probes available to label subcompartments, localize proteins, label membranes, respond to membrane potentials, sense the local chemical environment, read out molecular mobility, and provide many other measurements [20]. Coupled with antibodies, immunofluorescence labeling provides an easy method for detecting and localizing proteins or protein variants such as phosphorylated proteins. Cells can be engineered to express proteins tagged with any of the color variants of fluorescent proteins [21, 22], and these fluorescent proteins can be further engineered to create biosensors, indicators of specific cellular functions [16, 23-25].
- a variety of labels can be combined in a single sample preparation to provide for the measurement of many features in each individual cell in a population, as well as in the population as a whole [10, 26].
- Quantum dots with their single excitation wavelength and narrow emission bands, provide the potential for even higher degrees of multiplexing within an assay [27].
- the rainbow of fluorescent probes there are a number of bioluminescent and chemiluminescent reagents that can be effectively used in cell based assays [28, 29].
- Multiparameter High Content Screening Profiles A recent comparison of the performance of a panel of cytotoxicity assays, including DNA synthesis, protein synthesis, glutathione depletion, superoxide induction, Caspase-3 induction, membrane integrity and cell viability found that these assays on average had only half the predictive power of animal studies [11]. In contrast, a relatively simple four parameter high content screening assay using human hepatocytes was found to be more predictive than animal-based toxicity assays (O'Brien, P. J.; Irwin, W.; Diaz, D.; Howard-Cofield, E.; Krejsa, C. M.; Slaughter, M.
- Classification Tools A simple automated classifier has been developed for use with some commercially available assays. This classifier allows the use of Boolean operations to combine the outputs from several assay features into a single result [32]. These Boolean operations allow the assay developer to define an output that combines several feature measurements. This is useful in expanding the scope of some HCS assays, but has limited features, and is certainly not designed for, nor would it be easy to use with multidimensional feature sets.
- the invention described herein is an improved method for characterizing patient tissue specimens based on the integration of specific fluorescence labeling technologies with image acquisition and image analysis to create tissue marker profiles.
- the invention also discloses the use of the profiles to classify tissue specimens for the purposes of identifying patient medical conditions, such as tumor staging and other disease states, as well as response to treatment.
- One aspect of this invention is the integration of the use of traditional histological staining and transmitted light-based imaging with panels of molecularly specific, fluorescently labeled biomarkers to correlate morphometric interpretations with biomarker multiplexing in a “cellular systems biology profile.”
- the outcome is a powerful machine-learning platform where the instrument is fast and the software is simple.
- a number of instruments are available for transmitted light imaging of tissue sections.
- the Hamamatsu (Bridgewater, N.J.) NanoZoomer instrument allows automated processing of many slides per day.
- a number of instruments are available for fluorescent imaging of slides, including confocal microscope, wide-field imaging, and HCS systems. Both wide-field imaging systems and HCS systems can further make use of software deconvolution or structured illumination methods to improve resolution of features in the sections. Therefore, both traditional and more powerful, molecularly specific fluorescent reporters can be imaged in tissue sections on slides or in microplates.
- FIG. 3 illustrates the relationships between Systems Biology, Cellular systems biology, cellomics, Genomics, Proteomics and Metabolomics.
- Systems biology is the study of an organism, viewed as an integrated and interacting network of components, starting with genes, proteins, and biochemical pathways, that give rise to life. Because biological systems are complex, emergent properties result from interactions between system components. These emergent properties are properties that are not predicted from component properties, but are the result of interactions between components, and therefore require a systems approach to measurement and analysis.
- Cellular systems biology is the study of the cell as the basic unit of life: an integrated and interacting network of genes, proteins and biochemical reactions which give rise to functions and life.
- the cell is the simplest functional biological system, and therefore an ideal system from which to extract knowledge about biological systems.
- Cellular systems biology involves the application of cellular analysis technologies to the understanding of how the interactions of cellular components gives rise to the complex biochemical and molecular processes that contribute to cell functions. These cell functions include complex behavioral responses of cells to environmental changes as well as experimental treatments. As illustrated in FIG. 3 Cellular systems biology is a component of Systems Biology.
- the present invention relates to a method for identifying biological conditions in higher level organisms, including humans, from “systems-based” panel or panels of measurements of cellular and/or tissue features in tissue preparations, including blood, including sections, smears and other cellular tissue preparations.
- the “systems-based” panel of measurements within the same samples dramatically extends the present methodology that focuses on individual or a few parameters to the measurement and subsequent analysis of the systems response profile from the tissue investigated.
- the methods of this invention also provide a means to quantify the similarity of biological states and predicted modes of action based on the tissue system profiles.
- There are many applications which will benefit from the use of this invention including animal testing in drug discovery and environmental health, medical diagnostics and human clinical trials. Application of this technology will improve the efficiency and reduce the cost of drug development. The invention will also improve the efficiency of environmental toxicology testing.
- the invention includes various embodiments such as protocols, reagent panels, databases and informatics software.
- FIG. 5 illustrates an example of an embodiment of the invention which comprises a panel of assay function classes used to profile toxicity.
- function classes include Stress Pathways, Organelle Function, Cell Cycle Stage, Morphology Changes, Apoptosis and DNA Damage.
- Other function classes can be used in toxicity assessment and other functional applications of this method, as will be appreciated by a person of skill in the art.
- the methods of this invention can be used to validate additional assays and function classes which can be added to a profile to improve the sensitivity, specificity or range of applicability of a specific embodiment of this invention.
- one or more assays are selected to be used to measure one or more cellular systems biology features of cells within a tissue as an indication of a response in that assay function class.
- cellular systems biology feature measurements can be made on cells or tissues
- FIG. 6 a similar high content screening assay with multiple features for cells in arrays is illustrated in FIG. 6 .
- representative images from each channel of a multiplexed high content screen are shown.
- Algorithms are used to extract information from the images to produce outputs of at least four different cell features including nuclear size and shape, cell cycle distribution, DNA degradation, the state of the microtubule cytoskeleton, the activation state of the tumor suppressor p53, and the phosphorylation state of histone H3, a protein involved in the regulation of the cell cycle.
- Assays can be combined in two or more assay plates to produce a compound profile with six or more features.
- Assays such as this which include image analysis algorithms with multiple output features are available from a variety of commercial sources, especially HCS technology vendors such as Cellomics (Pittsburgh, Pa.), GE Healthcare (Piscataway, N.J.), Molecular Devices (Sunnyvale, Calif.), and others, and can be implemented in any one of the standard image analysis software packages.
- the output features from the combination of assays, both commercial and custom developed, are combined to form a single response profile.
- assays are selected from at least about four of the function classes in FIG. 5 , to provide a sufficiently broad profile for predicting higher level integrated functions.
- One embodiment of this invention employs a panel of assays with one from each of these function classes.
- assays are used first to build a predictive toxicology knowledgebase, and then to generate profiles of test compounds, to compare with the classes in the knowledgebase, and thereby to predict toxic affects of the test substances.
- Another embodiment of the invention uses all the assays listed in FIG. 5 to produce a more extensive profile, and then uses a statistical method such as principle components analysis to identify the features with the highest predictive power for a selected profile of toxicology parameters.
- analyses can include combinations of assays where individual tissue cells are measured, along with higher throughput assays where the population of tissue cells or a region of a tissue section is analyzed as a whole for morphometry, texture, intensity, or other features, as will be appreciated by a person of skill in the art.
- FIGS. 7 and 8 illustrate a flow diagram for two embodiments of the invention.
- the procedures in FIGS. 7 and 8 illustrate separate procedures.
- the procedure in FIG. 7 illustrates the procedure used to populate the tissue profile database and create the classes of response profiles linked to the histological determinations.
- the procedure in FIG. 8 illustrates the process for using the profile database to predict the classify tissue and identify medical states.
- the procedure in FIG. 8 comprises the following steps: 1. Tissue samples are prepared on slides or other carriers. 2. The tissues sections are fixed and stained with labels specific to the biomarker of interest. 3.
- the slides are read on an imaging system, such as an HCS reader, high throughput slide-scan reader, automated microscope or other detector. 4.
- Assay algorithms are applied to convert raw image data to assay data points. 5.
- the assay data points are clustered to produce response classes. 6. Responses classes are used to create a response profile for each of the classes. 7. Response profiles are established for the cells in control tissue specimens in each slide set. 8. Response profiles are clustered to identify unique profiles which can be used to classify and predict functional responses.
- the procedure illustrated in FIG. 8 is used to evaluate substances for physiological effects. It comprises a sequence of steps: 1. Samples are prepared on slides or other carriers. 2. The cells are fixed and stained with labels specific to the biomarker of interest. 3. The plates are read on an imaging system, such as an HCS reader, high throughput slide-scan reader, automated microscope or other detector. 4. Assay algorithms are applied to convert raw image data to assay data points. 5. The tissue cell features are classified based on the assay data points. 6. The database is searched for physiological response profiles that match the cellular response profiles. 7. Predictions for physiological responses are made based on similarity of response profiles. 8. A report is generated tabulating the probability of each physiological response based on the substance response data.
- FIG. 7 illustrates the overall sample flow while processing tissue sections to produce cellular systems biology profiles.
- a slide set comprises two or more tissue sections, each of which is used to collect a cellular systems biology profile.
- Each tissue section in the set produces an image set of images from one or more fields in each tissue section, at each of the wavelengths to be analyzed.
- Analysis of the image set produces a set of cellular systems biology features.
- the cellular systems biology features are processed and clustered to produce a cellular systems biology profiles to go into the data base, or to be used to search the data base to identify probable modes of physiological response or to set priorities for patient stratification.
- KS values are one means to characterize a population and provide a measurement that can be used to cluster samples from many patients or other tissue sources.
- cellular systems biology features based on KS values can be clustered by agglomerative clustering or other clustering methods, to build cellular systems biology profiles that identify tissues with similar cellular systems biology profiles.
- Other methods in addition to KS analysis can be used to process data prior to clustering, and a variety of clustering algorithms can be usefully applied.
- FIG. 8 illustrates one embodiment of the invention, wherein the data flow is used to generate response profiles for a panel of tissue samples or tissue assays.
- Tissue samples from sources with known conditions or medical outcomes are processed to produce cellular response profiles, which are merged with other information on physiological conditions.
- the combined profiles of each tissue are clustered to identify unique profiles that can be used to distinguish classes of response.
- the response classes are stored in a database for use in classifying test samples.
- Test tissue samples are processed to produce cellular response profiles that are then matched to those in the database, and based on the similarity of the response to the database profiles, probabilities are calculated for each of the reference response profiles in the database, producing a similarity profile.
- Algorithms The algorithms, custom designed or encapsulated in the application software provided by HCS vendors, or other imaging software providers, produce multiple numerical feature values (cellular systems biology features) such as subcellular object intensities, shapes, and location for each cell within an optical field.
- the vHCSTM Discovery Toolbox (Cellomics, Inc), Metamorph (Molecular Devices), software from GE Healthcare and other HCS and image analysis packages can be used to batch analyze images following acquisition. Contingent on the type of tissue sample and its preparation, the total number of cells measured per sample is typically in the range of at least about 100 to at least about 10000, depending on the heterogeneity of the cellular response and the sensitivity of the assay. Examples of assay output parameters illustrate the function of application software.
- the average nuclear intensity value for each cell can be used.
- Nuclear condensation produces larger average nuclear intensity values while nuclear enlargement accompanied by DNA degradation produced smaller average nuclear intensity values relative to normal cells.
- the measurement of histone H3 phosphorylation is obtained using the average nuclear intensity of cells labeled with antibodies specific for phosphohistone H3 as previously reported.
- KS goodness of fit analysis KS value
- the testing for significant changes in fluorescence-derived histograms is used to calculate KS values for replicate control samples and use these data to set a threshold (e.g., critical value), above which, a cellular systems biology feature response would be considered significant [36].
- the one-dimensional KS test can be adapted to two dimensions as described by Peacock [37] and further refined by Fasano and Franceschini [38].
- the two-dimensional cell population data distributions representing two physiological parameters from a cellular systems biology feature set are compared to the two-dimensional cell population data distributions obtained from multiple specimens.
- each distribution is divided into quadrants defined by the median x and y axis values calculated from the untreated cell data distributions.
- the two-dimensional KS value was then found by ranging through all four quadrants to find the maximal difference between the fraction of cells in each treated quadrant and the fraction of cells in each corresponding untreated quadrant.
- the heterogeneity of cell populations within tissues can also be analyzed with other statistical methods to evaluate cellular systems biology profiles.
- all the cell feature values from each cell are combined to create a cellular systems biology profile.
- the cellular systems biology profiles can consist of the actual measured values, and/or the principal components of the measured values, identified by standard methods [39, 40].
- the cellular systems biology features from each population of tissue cells and from different samples are clustered using standard methods [39, 40], to produce cellular systems biology profiles. These profiles are used to build a classifier. All the cells in a single tissue sample, and therefore characteristic of the same medical condition, are classified into these response classes. The percent occupation of each of these classes then becomes a population response profile for that sample.
- the cellular systems biology profiles from the samples are linked to the cellular systems biology profiles (e.g., toxicity response profiles) from the reference samples and stored in the database.
- the cellular systems biology profiles from the test samples are classified using a probabilistic classifier based on the cellular systems biology profiles of the reference samples in the database to predict toxicological responses or to stratify patients.
- Other embodiments use alternative analysis algorithms or methods to cluster cell response profiles and create a classifier based on the known properties of a training set of tissue sections.
- the liver a gland comprised of a host of cell types, performs both exocrine and endocrine functions that are regulated by appropriately orchestrated cellular activities. Furthermore, the liver is also responsible for the metabolism of drugs and steroids, many of which target their toxic activities to one or more cell types present in the liver. Other important functions of the liver include deiodination of triiodothyronine and thyroxine, gluconeogenesis and glycogenolysis, maintenance of normal glucose concentration in blood, etherification of free fatty acids into triglycerides, storage of glycogen, fat, and iron, detoxification of poisons and hydrogen peroxide, and hematopoiesis from the second to the eighth month of intrauterine life.
- a cellular systems biology characterization of cells within the intact structure of the liver provides one of the most relevant profiles of normal or diseased tissue, and the effects that chemical compounds have on the liver as a living system.
- liver is comprised of a stroma and a highly vascularized and innervated parenchyma. Tissue sections of liver will therefore be comprised of several cell types including:
- Nerve fibers cellular processes that accompany blood vessels to innervate the parenchyma
- Capillary endothelium cells forming the walls of blood vessels
- Fat cells store triglycerides
- Blood cells cells that include erythrocytes, immune cells, and platelets
- Hepatocytes the most prevalent cell type in the liver. Hepatocytes perform most of the functions of the liver listed above.
- biomarkers that can be combined in various combinations to profile the systems response of liver tissue to disease or compound treatment:
- Example of tissue preparation In one embodiment, a small animal such as a mouse or a rat is treated with one or more test compounds for various lengths of time (1 min to 21 d). In another embodiment, a small animal model of disease including metabolic models such as diabetes, cancer, or other models that either directly or indirectly involve the liver will be used. In yet another embodiment, human liver tissue from diseased or compound treated patients will be used. Normal, diseased, and treated tissue samples will be prepared. Tissue samples will be processed as either frozen sections or formaldehyde fixed paraffin-embedded sections. In addition, tissue samples will also be obtained for gene expression analysis.
- the optimal combination (multiplexing) of the liver tissue biomarkers will be the key to creating an optimal cellular systems biology profile of the tissue.
- the optimal number of number of multiplexed biomarkers will range from about four to about twelve biomarkers.
- Normal, diseased, and treated tissue samples will be prepared. Tissue samples will be processed as either frozen sections or formaldehyde fixed paraffin-embedded sections. In addition, tissue samples will also be obtained for gene expression analysis.
- liver tissue analysis 1. Below is an example of liver tissue analysis:
- Gene expression profiling is performed that compares “normal” liver tissue with tissues from diseased or compound treated animals.
- Gene expression informatics Gene expression profiles analyzed by informatics tools to characterize gene expression as a function of disease or compound treatment to identify gene products.
- lymphocytes e.g. CD3 and CD8.
- the level of immune cell activation, concentration and organization will be an important element of the profile.
- liver tissue slices are labeled for two or more biomarkers to profile differences between non-diseased and diseased or non-treated and treated animals.
- Biomarkers of a wide range of tissue functions are preferable since they provide breadth to the systems profile of the tissue.
- the number of biomarkers in one embodiment is about four to about ten biomarkers, and multiple biomarkers can be labeled in the same tissue section. This permits the comparison of some biomarker activities within the same cells.
- a rat is treated with an apoptosis-inducing compound such as paclitaxel or camptothecin for times ranging from about 30 min to about 21 d using multiple doses in the range from about 1 ⁇ g/kg up to about 100 mg/kg.
- an apoptosis-inducing compound such as paclitaxel or camptothecin for times ranging from about 30 min to about 21 d using multiple doses in the range from about 1 ⁇ g/kg up to about 100 mg/kg.
- the animal is sacrificed and the liver tissue either frozen and sectioned or fixed with a chemical such as formaldehyde and then impregnated with paraffin using standard methods before sectioning.
- a hematoxylin and eosin (H&E) stain can then be performed on one or more sections to provide a sample for traditional, transmitted light-based pathology interpretation.
- Other sequential sections can be labeled with combinations of fluorescent immunoreagents and physiological indicator dyes for image-based analysis, for
- Anti-cytochrome c as a biomarker of mitochondrial number, size and shape.
- Anti-alpha-tubulin as a biomarker of microtubule cytoskeletal remodeling.
- Anti-phospho-retinoblastoma protein as a biomarker of cell cycle checkpoint activity.
- Anti-NF-kappa-B as a biomarker of inflammation-related cell signaling.
- Anti-CD3 as a biomarker of lymphocyte infiltration into the tissue.
- Anti-activated-caspase 3 as a biomarker of apoptosis.
- Anti-PMP70 as a biomarker of peroxisome size and number.
- Anti-cytochrome P450 as a biomarker of hepatocyte metabolic activity.
- Cancer is a systems biology disease that requires a systems biology approach to create better stratification of individual patients for better diagnostics and treatments. Cancer is also an inflammatory process that involves the full range of the immune response. Therefore, tumors contain a combination of cancer cells at different stages of evolution, normal cells and an infiltration of the migratory immune cells such as dendritic cells, macrophages and lymphocytes. Tumor “cellular systems biology” characterization should therefore be a combination of tumor cell biomarkers and immune cell biomarkers. A key to tumor cellular systems biology is the use of a multiplexed panel of tumor biomarkers for cancer cells and immune cells that will better stratify patients.
- Stratification and diagnostic tests can be produced from either/or tissue-based profiles or peripheral blood profiles based on the tissue-based profile data.
- the multiplexed, fluorescence-based biomarkers can be a combination of specific reagents to detect specific proteins and post-translational modifications of the proteins, specific RNA species, including micro-RNA's either coding or non-coding in cells.
- RNA's are key “functional” read-outs.
- the expression of a gene is only one element of the systems biology and the present genomic tests are only correlations of gene expression without any functional information.
- Cellular functions are carried out primarily by proteins whose expression level, cellular localization and post-translational modification are responsible for carrying out normal and abnormal functions.
- Specific microRNA's have also been shown to be disease specific and are critical in regulating gene expression, similar to regulatory proteins.
- tumors are systems in that they are a complex integration of normal cells, a range of genetically evolving cancer cells and migrating immune cells. Therefore, a cellular systems biology profile of multiple protein and/or micro RNA biomarkers is important.
- the immune system becomes dysfunctional early in the process of cancer occurrence and continues throughout the evolution of the cancer stages leading to metastatic disease.
- the migratory immune cells are attracted to the growing tumors by pro-inflammatory cytokines and chemotactic factors.
- Tumor infiltrating lymphocytes release growth factors and cytokines that actually promote growth of the tumors, while the anti-tumor functions are weak or non-existent.
- Dendritic cells and tumor-associated macrophages present in the tumor exhibit phenotypes that demonstrate a supporting role for tumor growth.
- Regulatory T cells accumulate in the tumors, as well as in the tumor-draining lymph nodes and peripheral blood of patients. These latter cells actually protect tumor cells as part of the “recognition of self” immune process. Therefore, the immune system is mostly a tumor-promoting system and supports the progression and metastasis in most cancers.
- Gene expression fingerprints from tumor samples have been used to distinguish subtypes of breast cancers and to assign some prognostic index. These gene expression profiles usually identify genetic profile “signatures” indicative of the infiltration of the migratory immune cells. Unfortunately, in methods such as gene expression profiling, the disaggregated tumor samples the “tumor as a system” is lost since the whole tissue architecture and tumor cell-migratory immune cell structural relationships are lost.
- Tissue sections including tissue micro-arrays (TMA's) used in patient stratification and diagnostic tests are valuable, since the tumor “system” can be analyzed and quantified through the integrated use of traditional transmitted light stains that are standard in pathology and oncology with multiplexed fluorescence-based biomarkers of more functional parameters of both the migratory immune cells and the cancer cells. Therefore, the traditional information from pathology can be combined with panels of biomarkers using multiplexed fluorescence.
- TMA's tissue micro-arrays
- the tumor-draining and non-sentinel lymph nodes are important sites of tumor and immune system interactions that could aid in the “functional cellular systems biology signature”.
- the presence of tumor cells in the tumor-draining lymph nodes affects the types and numbers of immune cells within the nodes.
- the non-sentinel auxiliary nodes can also be influenced by local tumor growth, since it has been shown that CD4 T cells and dendritic cell counts have been used to predict survival in breast cancer patients.
- tumor progression also can be observed in the peripheral immune system by analysis of the circulating leukocytes, circulating T cells and other immune cells. Therefore, a correlative analysis of the patient's circulating immune cells in the peripheral blood with the tumor “system”, as well as lymph node “system” will create the an excellent opportunity to create powerful tests in tumors, lymph nodes and blood.
- biomarkers that can be combined in various combinations for optimal staging and diagnostic for breast cancer (in one embodiment, the combination of cancer cell and immune biomarkers may be most suitable):
- the optimal combination (also referred to herein as multiplexing) of the cancer cell and immune biomarkers, especially in the tumors, will be the determinative to creating an optimal cellular systems biology profile of the patient.
- the optimal number of number of multiplexed biomarkers is in the range from about four to about twelve biomarkers.
- tissue sections prepared from tumor samples. The first section labeled for H&E for traditional staging by a pathologist. The successive sections processed for multiplexed, fluorescence-based cytometry.
- lymphocytes e.g., CD3 and/or CD8.
- the level of immune cell activation, concentration and organization will be an important element of the profile.
- the percentage and ratios of specific migratory immune cells in tumors, tumor draining lymph nodes, non-sentinel lymph nodes and peripheral blood will be calculated and used build cellular systems biology profiles.
- Example percentage ranges of immune cells in tissues are as follows:
- Lymphocytes 1%-90% (distinct sub-types within this percentage)
- Eosinophils 0.01%-50%
- T-cell lymphocyte subtype I/T-cell lymphocyte subtype II 0.01-1000
- T-cell lymphocytes/B-cell lymphocytes 0.1-1000
- Dendritic cells/lymphocytes 0.01-1000
- Macrophages/lymphocytes 0.01-1000
- Lymphocyte sub-set/lymphocyte sub-set 0.01-1000
- biomarkers that suitably stratify patient samples from stage I to stage IV will be selected for profiling on new patients. New patients will allow the direct correlation of peripheral immune cells with the tumor tissue and lymph node sections.
- human brain tissue is obtained, fixed, and sectioned. A subset of sections are labeled with one or more stains to visualize morphological structures within the tissue associated with the pathology of Alzheimer's disease.
- a silver-based stain is used to visualize hallmarks of Alzheimer's disease such as neurite plaques and neurons with neurofibrillary tangles [41]. Analysis of the silver-stained tissue from multiple patients before, during, or after treatments with drugs provides data which are then entered into a profile.
- biomarkers that can be labeled using immunofluorescence approaches include A 42, A 40, von Willebrand factor, and the microtubule binding protein tau [42].
- Other biomarkers are also possible. These include phosphorylated APP (amyloid precursor protein) and unphosphorylated APP.
- biomarkers of other cellular processes can be included in the profile.
- Profiles built from multiple biomarker labels measured within tissues from a single patient or profiles built from biomarker labels measured in multiple patient tissue samples are clustered to identify unique profiles that can be used to classify and predict possible patient outcomes, or functional responses to drug treatments, or a combination of both.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Theoretical Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Multimedia (AREA)
- Quality & Reliability (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides an improved method for identifying and interpreting tissue specimens and/or cells derived from tissue specimens. A panel of cell-based reagents provides a number of readouts of cellular states or biomarkers that together define a profile of a diversity of cellular states or biomarkers in a tissue specimen representing the ‘systems” nature of biology. This cellular profile is interpreted using informatics tools, to identify similarities between specimens, in vivo medical conditions, and suggest options for treating medical conditions.
Description
- This application is a continuation of U.S. application Ser. No. 13/593,663 filed Aug. 24, 2012, which is a continuation of U.S. application Ser. No. 13/346,920 filed Jan. 10, 2012, which is a continuation of U.S. application Ser. No. 12/227,334 filed Apr. 14, 2009, now U.S. Pat. No. 8,114,615, which is the U.S. National Stage of International Application No. PCT/US2007/011865 filed May 17, 2007, published in English, which claims the benefit of U.S. Provisional Application No. 60/801,035, filed on May 17, 2006.
- The entire teachings of the above applications are incorporated herein by reference.
- The development of capabilities in multicolor fluorescence for applications in pathology were introduced more than a decade ago [3, 6-8] but still have not achieved wide market acceptance. In particular, Dow et al. [7] describe a study where multicolor fluorescence was used to determine lymphocyte phenotype and activation status in melanoma tissue sections through a process of human interactive image analysis. More recently, multicolor fluorescence has been applied in pathology [9] and HistoRx, Inc. (New Haven, Conn.) has commercialized some of these approaches. All of these publications and applications describe the use of fluorescence based imaging technology in tissue cell analysis, but are limited in their application and do not address the need to understand the systemic or cellular systems biology of a tissue.
- High content screening (HCS) and multiparameter HCS technologies were developed to automate cell analysis for drug discovery, HCS technologies are focused specifically on the measurement of individual targets or pathways in arrays of cultured cells treated with test compounds. However, HCS tools alone do not address the complete workflow of tissue based cellular systems biology.
- Thus, a need exists to provide methods for producing and analyzing cellular systems biology profiles in order to more fully understand the systemic and complex interaction of cellular biology systems.
- The cell is the simplest living system. Tissues are collections of specific cell types forming interacting colonies of cells. Although cells and tissues are less complex than a complete organism, they possess significant functional complexity allowing a detailed understanding of many aspects affecting a whole organism, such as the cellular basis of disease, treatment efficacy and potential toxicity of treatments. Multicolor fluorescence of multiplexed biomarkers coupled with searchable databases provides the basis for cellular systems biology (also referred to herein as systems cell biology) profiling and analysis.
- This invention provides for methods of analyzing and profiling, the analysis of, and means for profiling, tissue-based cellular systems biology. The cellular systems biology approach, including the combining of traditional histological staining with fluorescent staining to associate cellular and tissue markers that can be labeled by fluorescence has not been previously applied by others as now described herein. The use of the transmitted light images based on traditional histological stains used by pathologist as a “reference” image or “map” for better interpretation of the multiple fluorescence-based reagents as described herein will increase the acceptance of the systems approach by pathologists and will allow selection of a particular set of biomarkers for fluorescence analysis.
- In one embodiment of the invention, provided is a method for producing a cellular systems biology profile of one or more tissue samples. As used herein, “cellular systems biology” (also referred to herein as systems cell biology), is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions. Thus, a cellular systems biology profile is a systemic characterization of cells in the context of a tissue architecture such that the cells have particular characteristics dependent upon the relationships of different cells within a tissue and the biological or medical state of the tissue. It is the interactions, relationships, and state of the constituents of cells within a tissue that gives rise to the cellular systems biology features that are used to construct a profile. The interrelationships within a cellular systems biology profile are defined, for example, either arithmetically (e.g., ratios, sums, or differences between cellular systems biology feature values) or statistically (e.g., hierarchical clustering methods or principal component analyses of combinations of cellular systems biology feature values). In a particular embodiment, a cellular systems biology profile defines the interrelationships between a combination of at least five cellular systems biology features collected from cells within one or more tissue sections from the same sample.
- In one embodiment, the invention is directed to a method for producing one or more cellular systems biology profiles for one or more tissue samples, comprising obtaining at least two sections from one or more tissue samples. At least one section is labeled with a histological stain, to produce a histologically stained section. At least one other section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. In some embodiments the histologically stained section and the fluorescently stained section are the same or different. In a particular embodiment, the histologically stained section and the fluorescently stained section are different section. Each fluorescently labeled reagent is specific for a biomarker. As used herein, a “biomarker” is a molecule which provides a measure of cellular and/or tissue function. For example, and without limitation, a biomarker can be the measure of estrogen receptor expression levels, Her2/neu expression, transcription factor activation, location or amount or activity of a protein, polynucleotide, organelle, and the like, the phosphorylation status of a protein, etc. In one embodiment of the invention, the panel of fluorescently labeled reagents detects at least about four different biomarkers.
- The detection of a biomarker in one or more sections is a read-out of one or more features of the tissue. As used herein, a “feature” is a characteristic which provides a measurement or series of measurements of a particular biomarker (which can indicate a biological function) made in time and/or space within cells and tissues. Biological functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non-coding RNAs and proteins, morphology, state of differentiation, and the like. A single biomarker can provide a read-out of more than one feature. For example, Hoechst dye can be used to detect DNA (e.g., a biomarker), and a number of features of the tissue (e.g., nucleus size, cell cycle stage, number of nuclei, presence of apoptotic nuclei, etc.) can be identified by the DNA detected with the Hoechst dye.
- The method further comprises imaging the histologically stained section using a first optical mode, which produces a first set of data and imaging the fluorescently labeled section using a second optical mode, which produces a second set of data. The first set of data and the second set of data are analyzed to identify five or more features, such that at least one feature is identified in each of the first set of data and the second set of data. The combination of the five or more features generates a cellular systems biology profile of the one or more tissue samples.
- In a further embodiment of the invention, the cellular systems biology profile is stored in a database for reference, thereby providing a reference cellular systems biology profile in a database.
- In a further embodiment of the invention, the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples
- In another embodiment the method for producing a cellular systems biology profile of one or more tissue samples comprises obtaining at least one section from one or more tissue samples. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section, such that each fluorescently labeled reagent is specific for a biomarker. In one embodiment, the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method further comprises imaging the fluorescently labeled section with at least a first optical mode to produce a first set of data which is analyzed to identify at least about five or more features, wherein at least one feature is identified in the first set of data, and wherein the combination of the five or more features is a cellular systems biology profile the one or more tissue samples. Thus, the method produces a cellular systems biology profile of the one or more tissue samples. The method can further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
- In a further embodiment of the invention, provided herein is a method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer. As will be understood by a person of skill in the art, different cancers can be classified and staged according to their pathology. The method described herein permits, for example, the confirmation of the presence or absence of a cancer, the identification of a cancer, the classification of a cancer stage, the prediction and/or determination of the outcome or prognosis of the cancer, and the response of the cancer to any treatments. The method comprises obtaining at least two sections from one or more tissue samples. At least one section is labeled with a histological stain to produce a histologically stained section. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker. The panel of fluorescently labeled reagents comprises fluorescently labeled reagents which can be selected from the group consisting of: i) one or more fluorescently labeled reagents specific for at least four cancer cell biomarkers; ii) one or more fluorescently labeled reagents specific for at least four migratory immune cell biomarkers; iii) a combination of A) one or more fluorescently labeled reagents specific for at least three cancer cell biomarkers and B) one or more fluorescently labeled reagents specific for at least three migratory immune cell biomarkers, and iv) combinations of the above, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers. The detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method further comprises imaging the histologically stained section with at least a first optical mode to produce a first set of data and imaging the fluorescently labeled section with at least a second optical mode to produce a second set of data. The first set of data and second set of data are analyzed to identify at least about five or more features, such that at least one feature is identified in each of the first set of data and the second set of data. The combination of the five or more features is a cellular systems biology profile of the one or more tissue samples, and thus the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or the absence of a cancer. In one embodiment, the one or more tissue samples is selected from the group consisting a suspected or known cancerous tissue, a lymph node, and a combination thereof.
- In a still further embodiment of the invention, the method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples
- In another embodiment of the invention, provided herein is a method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity. The method comprises obtaining at least two sections from one or more tissue samples. At least one section labeled with a histological stain to produce a histologically stained section and at least one section is with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker. The panel of fluorescently labeled reagents comprises a set of fluorescently labeled reagents selected from the group consisting of i) one or more fluorescently labeled reagents specific for cell metabolism biomarkers, ii) one or more fluorescently labeled reagents specific for DNA damage biomarkers, iii) one or more fluorescently labeled reagents specific for cell morphology biomarkers, iv) one or more fluorescently labeled reagents specific for DNA damage biomarkers, v) one or more fluorescently labeled reagents specific for cell differentiation biomarkers, vi) one or more fluorescently labeled reagents specific for stress-induced transcription activation or inhibition biomarkers, vii) a one or more fluorescently labeled reagents specific for phosphorylation status of stress kinase biomarkers, viii) one or more fluorescently labeled reagents specific for apoptosis or necrosis biomarkers, ix) one or more fluorescently labeled reagents specific for cytoskeleton biomarkers, x) one or more fluorescently labeled reagents specific for organelle biomarkers, xi) one or more f fluorescently labeled reagents specific for presence or activation of immune cell biomarkers, and xii) combinations thereof, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The histologically stained section is imaged with at least a first optical mode to produce a first set of data. The fluorescently labeled section is imaged with at least a second optical mode to produce a second set of data. The method further comprises analyzing the first set of data and second set of data to identify at least about five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data. The combination of the five or more features is a cellular systems biology profile of the one or more tissue samples. Thus, the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity. In one embodiment, the one or more tissue samples is one or more liver tissue samples.
- The foregoing will be apparent from the following more particular description of example embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments of the present invention.
-
FIG. 1 are examples of slides for Tissue Profiling.FIG. 1A isSample # 01, which represents a slide that combines a tissue section labeled with H&E stain, and a sequential section labeled with fluorescent tags for specific biomarkers.FIG. 1B isSample # 02, which illustrates a slide with an H&E stained section, a fluorescent labeled section and some cells isolated from patient tissue and labeled with fluorescent tags (pictures of sections and cells are all enlarged for illustrative purposes). -
FIG. 2 is a schematic of systems cell biology (also referred to herein as cellular systems biology) profiling, which involves the analysis of a diverse set of cellular biomarkers used to identify features to create a profile.FIG. 2A represent cells from a patient that are, e.g., healthy, diseased or being treated or have been treated with a drug.FIG. 2B schematically represents the analysis of a set of biomarkers.FIG. 2C represents a panel of cellular biomarkers used to produce cellular systems biology profile. These profiles are stored in a database (schematically shown inFIG. 2D ), which can be used a reference database. Comparison of a patient profile with reference profiles is used e.g., as a predictive tool, or to associate a biomarker, feature or a profile with a specific medical condition, or to evaluate new profiles. -
FIG. 3 is a schematic illustrating the interrelation of systems cell biology which captures enough complexity to correlate biomarkers with higher level organ and organism effects, while allowing high throughput and cost-effective profiling. Cellular systems biology and systems biology are based on the interactions and relationships between the fundamental components of living systems represented by the “-omics” and a selection of specific cellular biomarkers are obtained from a combination of genomics, proteomics and metabolomics, in the context of the cells studied (cellomics). -
FIG. 4 is a schematic of how a cell integrates the many processes illustrated, such as gene expression, energy metabolism, etc. to yield normal functions. Diseases result from the dysregulation of one or more of these cellular processes which often results in complex symptoms. Many of these processes share pathways, signals and proteins and therefore should be investigated as part of the cell system (including the collection of cells of different types in tissues). -
FIG. 5 illustrate examples of biomarkers for use in patient tissue profiling selected from function classes that include, for example: (A) Stress Pathways; (B) Organelle Function; (C) Cell Cycle; (D) Morphology; (E) Apoptosis; and (F) DNA Damage, as well as micro RNA, and migratory immune cells. Specific combinations of biomarkers are selected for analysis of particular disease conditions, as described herein. -
FIG. 6 is an example of the multiplexed labeling of cells with a panel of biomarkers such as would be used in tissue sections. Labels are multiplexed in tissue which allows analysis of correlations between biomarker activation within the same tissue, and to reduce the number of sections that must be prepared and analyzed. In a particular embodiment, at least four or more biomarkers are analyzed in each section. -
FIG. 7 is a schematic flow chart of the process of creating a reference profile database as described in one embodiment of the invention. Box 1: Sequential tissue sections are prepared and mounted. Box 2(a): One section is labeled with H&E stain for transmitted light imaging or review. Box 2(b): A second section is labeled with a panel of fluorescent labels to measure biomarkers. Boxes 3(a & b): Sections are imaged or viewed for interpretation. Boxes 4(a & b): Sections are analyzed and/or interpreted to create data. Box 5: Data from the sequential sections are compared and combined. Box 6: The cellular systems profile is added to database. Box 7: Tissue profiles in database are clustered to identify similarities. Box 8: Profile classes are identified. Box 9: Correlations between systems profiles and histological data are used to build a classifier which is stored in the database. -
FIG. 8 is a flow chart illustrating the process of analyzing and classifying tissue, e.g., from a patient. -
FIGS. 9A-I is a flow chart illustrating the overall process for automated tissue profiling in one embodiment of the invention.FIG. 9(A) Process starts with reference tissue with know medical history.FIG. 9(B) Profiles from fluorescence analysis are combined with results from human interpretation of stained sections along with medical history;FIG. 9(C) to build a classifier andFIG. 9(D) populate a reference database.FIG. 9(E) Patient tissues areFIG. 9(F) prepared, analyzed andFIG. 9(G) classified to identifyFIG. 9(H) similarities to other patient profiles (patient stratification) andFIG. 9(I) to make predictions regarding medical conditions, or medical outcomes. -
FIG. 10 is a flow chart of the process for selecting biomarkers for a cancer tissue profiling panel. Box (1) Normal tissue from Patient is (Box 2) analyzed by Gene Expression profiling. Box (3) A sample of tumor tissue from the same patient is (Box 4) analyzed by Gene Expression Profiling and is (Box 5) staged in the traditional manner. This combined information, comparing “normal” tissue with patient tumor tissue is (Box 6) used to identify potential biomarkers. Box (7) Gene products are prioritized based on known reference points including Her2/Neu and then antibodies acquired or produced to create test panels (Box 8). The design of the biomarker panel is based on the selection of combinations of cancer cell biomarkers that are multiplexed for fluorescence-based immunohistochemistry (IHC). -
FIG. 11 is an overview of one embodiment of the invention. Tissue samples from a patient (A) which could include healthy tissue, tumor tissue, other diseased tissue or a blood specimen are processed by standard methods for mounting on slides (B) either as individual sections or as tissue microarrays. Slides are imaged on a microscope or other imaging system (C). Images are interpreted either by a pathologist or through the application of image analysis algorithms to produce data (D) which can be stored in a database. The combination of the data from a single specimen forms a cellular systems profile of that specimen. Data from multiple cellular systems profiles are analyzed using statistical methods including cluster analysis, principle component analysis, and other multifactorial methods to identify similarities between profiles which can be represented in a clustered heat map (E), identify patterns within a profile that indicate a certain biological or medical state, and to classify tissue status based on similarity in profiles. The information provided by cellular systems biology profiling is used by the physician or scientist (F) to better understand the biology or progression of a disease or biological condition, to more precisely stratify patients in a clinical trial and/or to optimize a therapeutic approach (G) to treating a condition. - “Cellular systems biology” is defined as the investigation of the integrated and interacting networks of genes, proteins, and metabolic reactions that give rise to function and life. Cells in tissues, as complex systems, exhibit properties that are not anticipated from the analysis of individual components, known as emergent properties that require analysis of many factors to characterize cellular states. Taylor and Giuliano [10] describe the application of in vitro cell systems analysis to drug discovery. In this analysis, correlation between measurements in individual cells was required to identify and interpret cell responses to drug treatment.
- “Cellular systems biology features” are defined as a data measurements or a series of measurements of a particular biological function (typically evidenced by the presence, absence and/or level of one or more biomarkers) made in time and/or space within cells and tissues. Examples of biological functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non-coding RNAs and proteins.
- Cellular Systems Biology analysis of cells in tissues makes use of some of the cell analysis algorithms developed for High Content Screening (HCS). “HCS” is defined as a technology platform designed to measure the temporal and spatial activities of genes, proteins, and other cellular constituents in living cells in response to drug treatment (Giuliano, K. A.; Haskins, J. R.; Taylor, D. L., Advances in high content screening for drug discovery. ASSAY and
Drug Development Technologies 2003, 1, 565-577). HCS and multiparameter HCS were developed to measure individual targets or pathways in arrays of cultured cells in response to drug treatment. However, as described herein, HCS image analysis tools can also be used to extract data from cells in tissues as part of a cellular systems biology profiling approach that would enable the characterization of complex and emergent properties that arise in living cells and tissue. In addition, numerous other image analysis software packages, including those that are supplied with microscope slide scanning systems could be applied to extract cellular features from images of tissues to build a cellular systems biology profile. - “Cellular systems biology profiles” are defined as the interrelationships between combination of at least about five cellular systems biology features collected from cells within one or more tissue sections from the same sample. These interrelationships are calculated either arithmetically (e.g., ratios, sums, or differences between cellular systems biology feature values) or statistically (e.g., hierarchical clustering methods or principal component analyses of combinations of cellular systems biology feature values). Cellular systems biology profiles can be used to understand the complex response of cells and tissues to disease and various treatments by characterizing the emergent properties of the cellular systems response.
- “Emergent properties” refers to the arising of novel and coherent structures, patterns, and properties during the process of self-organization in complex systems (Goldstein, Jeffrey (1999), “Emergence as a Construct: History and Issues”, Emergence: Complexity and Organization 1: 49-72). The emergent properties of cells and tissues (e.g., growth and division, transformation to a tumor phenotype, etc.) cannot begin to be defined until a systemic analysis of complex cellular function is undertaken. Emergent properties are not anticipated from the analysis of individual components, but require analysis of many factors to characterize cellular states.
- Although the analysis of single, individual features in tissue sections has value, the application of a “systems approach” wherein, as provided herein, multiple features (e.g., at least about four features, at least about five features, at least about six features, at least about 7-12 features, or more), of a tissue are analyzed, enables a more precise determination of the state of the cells, the tissues, and the organism as a whole. Furthermore, this approach facilitates, for example, the automation of tissue analysis, and the production of tissue profiles for more precise tumor staging, personalized treatments, evaluation of treatment efficacy, and early indication of side effects, as well as improved analyses in animal toxicology studies in drug discovery.
- Systems Biology and Cellular Systems Biology: The cell is the simplest living system. Tissues are collections of specific cell types forming interacting colonies of cells. Although cells and tissues are less complex than a complete organism, they possess significant functional complexity allowing a detailed understanding of the cellular basis of disease, treatment efficacy and potential toxicity of treatments. Multicolor fluorescence of multiplexed biomarkers coupled with searchable databases provides the basis for systems cell analysis.
- Prior to this invention, the analysis and profiling of tissue-based cellular systems biology has not been described. The cellular systems biology approach, including the combining of traditional histological staining with fluorescent staining to associate cellular and tissue markers that can be labeled by fluorescence has not been previously done by others as now described herein. The use of the transmitted light images based on traditional (non-fluorescent) histological stains used by pathologist as a “reference” image or “map” for better interpretation of the multiple fluorescence-based reagents as described herein will increase the acceptance of the systems approach by pathologists and will allow the selection of a specific set of biomarkers for fluorescence analysis.
- In one embodiment of the invention, provided is a method for producing a cellular systems biology profile of one or more tissue samples. As used herein, “cellular systems biology” (also referred to herein as systems cell biology), is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions. Thus, a cellular systems biology profile is a systemic characterization of cells in the context of a tissue architecture such that the cells have particular characteristics dependent upon the relationships of different cells within a tissue and the biological or medical state of the tissue. It is the interactions, relationships, and state of the constituents of cells within a tissue that gives rise to the cellular systems biology features that are used to construct a profile. The interrelationships within a cellular systems biology profile are defined or calculated, for example, either arithmetically (e.g., ratios, sums, or differences between cellular systems biology feature values) or statistically (e.g., hierarchical clustering methods or principal component analyses of combinations of cellular systems biology feature values). In a particular embodiment, a cellular systems biology profile defines the interrelationships between a combination of at least about five cellular systems biology features collected from cells within one or more tissue sections from the same sample. In another embodiment, a cellular systems biology profile is the combination of at least about six, seven, eight, nine, ten, eleven, twelve, or more features.
- In one embodiment of the invention, the method comprises obtaining at least two sections from one or more tissue samples. Any suitable tissue sample can be used in the methods described herein. For example, the tissue can be epithelium, muscle, organ tissue, nerve tissue, tumor tissue, and combinations thereof. In one embodiment, blood is not a tissue sample. Samples of tissue can be obtained by any standard means (e.g., biopsy, core puncture, dissection, and the like, as will be appreciated by a person of skill in the art). At least one section is labeled with a histological stain, to produce a histologically stained section. As used in the invention described herein, histological stains can be any standard stain as appreciated in the art, including but not limited to, alcian blue, Fuchsin, haematoxylin and eosin (H&E), Masson trichrome, toluidine blue, Wright's/Giemsa stain, and combinations thereof. As will be appreciated by a person of skill in the art, traditional histological stains are not fluorescent. At least one other section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. As used in the invention described herein, the panel of fluorescently labeled reagents comprises a number of reagents, such as fluorescently labeled antibodies, fluorescently labeled peptides, fluorescently labeled polypeptides, fluorescently labeled aptamers, fluorescently labeled oligonucleotides (e.g. nucleic acid probes, DNA, RNA, cDNA, PNA, and the like), fluorescently labeled chemicals and fluorescent chemicals (e.g., Hoechst 33342, propidium iodide, Draq-5, Nile Red, fluorescently labeled phalloidin), and combinations thereof. Each fluorescently labeled reagent is specific for at least one biomarker. As used herein, a “biomarker” is a molecule which provides a measure of cellular and/or tissue function. For example, and without limitation, a biomarker can be the measure of receptor expression levels, (e.g., estrogen receptor expression levels, Her2/neu expression); transcription factor activation; location or amount or activity of a protein, polynucleotide, organelle, and the like; the phosphorylation status of a protein, etc. In one embodiment, a biomarker is a nucleic acid (e.g., DNA, RNA, including micro RNAs, snRNAs, mRNA, rRNA, etc.), a receptor, a cell membrane antigen, an intracellular antigen, and extracellular antigen, a signaling molecule, a protein, and the like. In one embodiment of the invention, the panel of fluorescently labeled reagents detects at least about four different biomarkers. In another embodiment of the invention, the panel of fluorescently labeled reagents detects at least about four to about six, to about ten, to about twelve different biomarkers or more. In another embodiment of the invention, the panel of fluorescently labeled reagents detects at least about three different biomarkers. In a further embodiment, each fluorescently labeled reagent has different fluorescent properties, which are sufficient to distinguish the different fluorescently labeled reagents in the panel.
- The detection of a biomarker in one or more sections is a read-out of one or more features of a cellular systems biology profile. As used herein, a “feature” is a characteristic which provides a measurement or series of measurements of a particular biomarker (which can indicate a biological function) made in time and/or space within cells and tissues. Biological functions include, but are not limited to: protein posttranslational modifications such as phosphorylation, proteolytic cleavage, methylation, myristoylation, and attachment of carbohydrates; translocations of ions, metabolites, and macromolecules between compartments within or between cells; changes in the structure and activity of organelles; and alterations in the expression levels of macromolecules such as coding and non-coding RNAs and proteins, morphology, state of differentiation, and the like. A single biomarker can provide a read-out of more than one feature. For example, Hoechst dye detects DNA, which is an example of a biomarker. A number of features can be identified by the Hoechst dye in the tissue sample such as nucleus size, cell cycle stage, number of nuclei, presence of apoptotic nuclei, etc.
- The method further comprises imaging the histologically stained section using a first optical mode, which produces a first set of data and imaging the fluorescently labeled section using a second optical mode, which produces a second set of data. As will be appreciated by the person of skill in the art, as used in the invention described herein, the optical mode for imaging can be any mode suitable for this use, e.g., transmitted light microscopy, fluorescence light microscopy, wide field microscopy, confocal microscopy, and combinations thereof, as appropriate. In one embodiment, the data produced in either or both of the first set of data and second set of data can be digital data. The first set of data and the second set of data are analyzed to identify five or more features, such that at least one feature is identified in the first set of data and at least one feature is identified in the second set of data. The combination of the five or more features generates a cellular systems biology profile of the one or more tissue samples.
- In one embodiment of the invention, the imaging procedures are automated. Furthermore, analyzing the data can be performed manually, by automation or a combination thereof. As will be appreciated by a person of skill in the art, imaging a histologically stained section and imaging a fluorescently labeled section can be done sequentially or simultaneously. In addition, histological labeling and fluorescent labeling can be done sequentially or simultaneously. In some embodiments, after obtaining one or more sections from a tissue sample, the method is wholly automated.
- In a further embodiment of the invention, the method further comprises comparing the cellular systems biology profiles of two or more tissue samples in order to identify similarities, differences, or combinations thereof, of the two or more tissue samples. In one embodiment, the two or more tissue samples are serial sections from a single tissue specimen. Serial sections of a single tissue sample are tissue sections which were adjacent to each other in the preparation of two or more sections from a tissue sample.
- In one embodiment of the invention, the one or more tissue samples are isolated from one or more animals. For example, in one embodiment, the one or more animals are one or more humans. In a particular embodiment, one or more tissue samples are isolated from a human patient at one or more time points, such that at least one tissue sample is isolated from each time point from the same patient.
- In another embodiment of the invention, the panel of fluorescently labeled reagents indicate the presence, amount, location, activity, distribution, or combination thereof, of the biomarkers in the fluorescently labeled section. The location of a biomarker can be intracellular, extracellular, within specific intracellular locations, at specific extracellular locations, and combinations thereof. Activity of a biomarker can be the activation state of the biomarker (such as indicated, e.g., by its phosphorylation state, conformation state, or intracellular location, and the like).
- In a further embodiment of the invention, the cellular systems biology profile is stored in a database for reference, thereby providing a reference cellular systems biology profile in a database. In one embodiment, the database is a computer. In another embodiment, the database is stored on a server. In one embodiment, the reference cellular systems biology profile in the database is compared with a cellular systems biology profile of one or more further samples. This permits the identification of similarities, differences, or a combination thereof, of the cellular systems biology profile of the one or more further samples and the reference cellular systems biology profile. Various methods can be used to compare the cellular systems biology profile of the one or more further samples and the cellular systems biology profile in the database, such as by graphical display, cluster analysis, or statistical measure of correlation and combinations thereof.
- In a further embodiment of the invention, the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of at least one blood sample obtained from the same source as the one or more tissue samples. In one embodiment, the blood sample is a peripheral blood sample. Peripheral blood is the cellular components of blood, consisting of red blood cells, white blood cells, and platelets, which are found within the circulating pool of blood and not sequestered within the lymphatic system, spleen, liver, or bone marrow. The method comprises obtaining at least one blood sample smear from at least one peripheral blood sample from the same source as the one or more tissue samples. As used in the invention described herein, peripheral blood samples can be obtained by any standard procedure. The at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker. In one embodiment, the panel of fluorescently labeled reagents detects at least about four different biomarkers. The detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method further comprises imaging the fluorescently labeled blood sample smear with at least a third optical mode, such that the imaging produces a third set of data. The third set of data is analyzed to identify at least about five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear. This method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples. In one embodiment, the at least one peripheral blood sample is taken at the same or different time point as the one or more tissue samples are obtained. In another embodiment, more than one peripheral blood sample is taken at different time points, and the cellular systems biology profiles of the more than one peripheral blood samples are compared.
- In another embodiment of the invention, the method for producing a cellular systems biology profile of one or more tissue samples further comprises producing a cellular systems biology profile of one or more peripheral blood samples obtained from the same source as the one or more tissue samples. The method comprises obtaining at least two blood sample smears from one or more peripheral blood samples. At least one blood sample smear is labeled with a histological stain to produce a histologically stained blood sample smear. In addition, at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear. Each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least about four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The histologically stained blood sample smear is imaged with at least a third optical mode to produce a third set of data. The fluorescently labeled blood sample smear is imaged with at least a fourth optical mode to produce a fourth set of data. The third set of data and the fourth set of data are analyzed to identify at least about five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, such that the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears. Thus the method produces a cellular systems biology profile of the one or more peripheral blood samples obtained from the same source as the one or more tissue samples. As discussed above, in one embodiment, the one or more peripheral blood samples are taken at the same or different time point as the one or more tissue samples are obtained. Furthermore, in another embodiment, when one or more peripheral blood samples are taken at different time points, the cellular systems biology profiles of the one or more peripheral blood samples are compared.
- In an additional embodiment of the invention, provided herein is a method for producing a cellular systems biology profile of one or more tissue samples. The method comprises obtaining at least one section from one or more tissue samples. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section, such that each fluorescently labeled reagent is specific for a biomarker. In one embodiment, the panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method further comprises imaging the fluorescently labeled section with at least a first optical mode to produce a first set of data which is analyzed to identify at least about five or more features, wherein at least one feature is identified in the first set of data, and wherein the combination of the five or more features is a cellular systems biology profile the one or more tissue samples. Thus, the method produces a cellular systems biology profile of the one or more tissue samples. In a further embodiment, the method further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples. The method comprises obtaining at least one blood sample smear from at least one peripheral blood sample. The at least one blood sample smear is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, such that each fluorescently labeled reagent is specific for a biomarker. The panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method further comprises imaging the fluorescently labeled blood sample smear with at least a second optical mode to produce a second set of data. The second set of data is analyzed to identify at least about five or more features, such that the five or more features is a cellular systems biology profile of the at least one blood sample smear. Thus, the method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples. In an optional embodiment, the method further comprises labeling at least one blood sample smear with a histological stain to produce a histologically stained blood sample smear. The histologically stained blood sample smear is imaged to produce an additional set of data which is analyzed to identify at least one feature, wherein the combination of the five or more features identified in the combination of the histologically stained blood sample smear and the fluorescently stained blood sample smear is a cellular systems biology profile of the one or more blood sample smears.
- In a further embodiment of the invention, provided herein is a method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer. As will be understood by a person of skill in the art, different cancers can be classified and staged according to their pathology. The method described herein permits, for example, the confirmation of the presence or absence of a cancer, the identification of a cancer, the classification of a cancer stage, the prediction and/or determination of the outcome or prognosis of the cancer, and the response of the cancer to any treatments. The method comprises obtaining at least two sections from one or more tissue samples. At least one section is labeled with a histological stain to produce a histologically stained section. At least one section is labeled with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker. The panel of fluorescently labeled reagents comprises fluorescently labeled reagents which can be selected from the group consisting of: i) a set of fluorescently labeled reagents specific for at least four cancer cell biomarkers; ii) a set of fluorescently labeled reagents specific for at least four migratory immune cell biomarkers; iii) a combination of A) a set of fluorescently labeled reagents specific for at least three cancer cell biomarkers and B) a set of fluorescently labeled reagents specific for at least three migratory immune cell biomarkers, and iv) combinations of the above, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers. The detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method further comprises imaging the histologically stained section with at least a first optical mode to produce a first set of data and imaging the fluorescently labeled section with at least a second optical mode to produce a second set of data. The first set of data and second set of data are analyzed to identify at least about five or more features, such that at least one feature is identified in each of the first set of data and the second set of data. The combination of the five or more features is a cellular systems biology profile of the one or more tissue samples, and thus the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or the absence of a cancer. In one embodiment, the cancer is breast cancer.
- In a further embodiment, the fluorescently labeled reagents specific for cancer cell biomarkers detect cancer cell markers such as HER2/neu, estrogen receptor (ER), Ki-67, Cox-2, p16 and the like. In another embodiment, the fluorescently labeled reagents specific for migratory immune cell biomarkers detect migratory immune cell biomarkers such as NK cell biomarkers, LAK cell biomarkers, TRAIL, PD1, biomarkers of immune cell apoptosis, and the like. In an additional embodiment, a feature is a ratio of different migratory immune cell subtypes as detected by the migratory immune cell biomarkers, such that the ratio is indicative of the presence of a cancer, the stage of cancer, the diagnosis of a cancer, the prognosis of a cancer, the absence of a cancer and combinations thereof.
- In a further embodiment, the one or more tissue samples is selected from the group consisting a suspected or known cancerous tissue, a lymph node, and a combination thereof.
- Migratory immune cells are typically white blood cells (leukocytes). In one embodiment, examples of migratory immune cell biomarkers include, without limitation, the percentage and ratios of specific migratory immune cells in tumors, tumor draining lymph nodes, non-sentinel lymph nodes and peripheral blood. Examples of migratory immune cells in normal blood include: (1) lymphocytes (25% of white blood cells) which includes T-cells (distinct sub-types), B-cells (distinct sub-types), and natural killer (NK) cells; (2) Neutrophils (65% of white blood cells); (3) Eosinophils (4% of white blood cells) and (4) Monocytes (6% of white blood cells), which includes macrophages (distinct sub-types). In one embodiment, the percentage ranges of immune cells in tissues for cellular systems biology profiling comprise one or more of the following: lymphocytes from about 1% to about 90% (with distinct sub-types within this percentage, as will be recognized by a person of skill in the art); neutrophils from about 1% to about 90%; eosinophils from about 0.01% to about 50%; monocytes from about 0.01% to about 50% (with distinct sub-types within this percentage, as will be recognized by a person of skill in the art). In another embodiment of the invention, the ranges of ratios of immune cells in tissues for cellular systems biology profiling comprise one or more of the following: T-cell lymphocytes/B-cell lymphocytes from about 0.1 to about 1000; dendritic cells/lymphocytes from about 0.01 to about 1000; macrophages/lymphocytes from about 0.01 to about 1000; lymphocyte sub-set/lymphocyte sub-set from about 0.01 to about 1000.
- In a still further embodiment of the invention, the method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples. The method comprises obtaining at least one blood sample smear from at least one peripheral blood sample and labeling the at least one blood sample smear with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear. Each fluorescently labeled reagent is specific for a biomarker, and the panel of fluorescently labeled reagents detects at least about four different biomarkers. The detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method further comprises imaging the fluorescently labeled blood sample smear with at least a third optical mode to produce a third set of data. The third set of data is analyzed to identify five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear. Thus, the method produces a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples. In one embodiment, the at least one peripheral blood sample is taken at the same or different time point as the one or more tissue samples are obtained. In another embodiment, more than one peripheral blood sample is taken at different time points, and the cellular systems biology profiles of the more than one peripheral blood samples are compared.
- In a still further embodiment of the invention, the method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer and/or the absence of a cancer further comprises producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples. The method comprises obtaining at least two blood sample smears from one or more peripheral blood samples and labeling at least one blood sample smear with a histological stain to produce a histologically stained blood sample smear. The method further comprises labeling at least one blood sample smear with a panel of fluorescently labeled reagents to produce a fluorescently labeled blood sample smear, such that each fluorescently labeled reagent is specific for a biomarker. The panel of fluorescently labeled reagents detects at least about four different biomarkers, and the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The method also comprises imaging the histologically stained blood sample smear with at least a third optical mode to produce a third set of data and imaging the fluorescently labeled blood sample smear with at least a fourth optical mode to produce a fourth set of data. The third set of data and the fourth set of data are analyzed to identify at least about five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, such that the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears. Thus, the method produces a cellular systems biology profile of one the or more peripheral blood samples obtained from the same source as the one or more tissue samples, wherein the tissue sample is profiled for the presence or absence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer of the absence of a cancer. In one embodiment, the one or more peripheral blood samples are taken at the same or different time points as the one or more tissue samples are obtained. In another embodiment, more than one peripheral blood samples are taken at different time points, and the cellular systems biology profile of the more than one peripheral blood samples are compared.
- In another embodiment of the invention, provided herein is a method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity. The method comprises obtaining at least two sections from one or more tissue samples. At least one section labeled with a histological stain to produce a histologically stained section and at least one section is with a panel of fluorescently labeled reagents to produce a fluorescently labeled section. Each fluorescently labeled reagent is specific for a biomarker. The panel of fluorescently labeled reagents comprises a set of fluorescently labeled reagents selected from the group consisting of i) a set of fluorescently labeled reagents specific for cell metabolism biomarkers, ii) a set of fluorescently labeled reagents specific for DNA damage biomarkers, iii) a set of fluorescently labeled reagents specific for cell morphology biomarkers, iv) a set of fluorescently labeled reagents specific for DNA damage biomarkers, v) a set of fluorescently labeled reagents specific for cell differentiation biomarkers, vi) a set of fluorescently labeled reagents specific for stress-induced transcription activation or inhibition biomarkers, vii) a set of fluorescently labeled reagents specific for phosphorylation status of stress kinase biomarkers, viii) a set of fluorescently labeled reagents specific for apoptosis or necrosis biomarkers, ix) a set of fluorescently labeled reagents specific for cytoskeleton biomarkers, x) a set of fluorescently labeled reagents specific for organelle biomarkers, xi) a set of fluorescently labeled reagents specific for presence or activation of immune cell biomarkers, and xii) combinations thereof, such that the panel of fluorescently labeled reagents detects at least about four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile. The histologically stained section is imaged with at least a first optical mode to produce a first set of data. The fluorescently labeled section is imaged with at least a second optical mode to produce a second set of data. The method further comprises analyzing the first set of data and second set of data to identify at least about five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data. The combination of the five or more features is a cellular systems biology profile of the one or more tissue samples. Thus, the method produces a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity. In one embodiment, the one or more tissue samples is one or more liver tissue samples.
- As will be understood by a person of skill in the art, the methods of the invention as described herein can be used in many applications. The invention advances technologies currently in practice, some of which are outlined herein.
- Staining and Transmitted Light Imaging in Pathology, Toxicology and Personalized Medicine: Standard histological methods for staining and imaging of tissue sections in Pathology, and Toxicology were developed to meet the needs of pathologists and toxicologists to view the sections and make a determination based on experience and knowledge. Stains such as H&E (Hematoxylin and Eosin), congo red, Gram bacterial stain and others provide the means to label various cell types and structures, to facilitate interpretation. Although experienced pathologists can learn to interpret the staining patterns, efforts to automate the interpretation of the patterns have met with great difficulty. Fluorescent labeling technologies, especially when coupled with antibodies or other molecularly specific biomarkers or tags such as aptamers, allow for very specific labeling of cellular components, high signal to background, the ability to distinguish multiple labels on a single specimen, and the ability to detect comparatively small numbers of targets in each cell. While these properties make fluorescence nearly ideal for automated imaging, the use of fluorescence in visual interpretation is more limited due to bleaching, limited spectral response of the eye, and the limited dynamic range of the eye. Efforts to automate pathology have principally been guided by the staining and interpretation methods used by the pathologist.
- Software tools have been developed to automate the acquisition, and management of images from tissue sections. For example, the Bacus Laboratories, Inc. (Chicago, Ill.) has developed software to analyze transmitted light tissue sections and tissue arrays along with software tools for image sharing and remote analysis.
- Drug Discovery: On average, pharmaceutical companies spend more than $1 billion to bring a new drug to market, yet despite this large investment of time and resources, the frequency of drug failure is high. Poor efficacy and drug induced toxicity continue to be major causes of these failures [11, 12]. Furthermore, many candidate drugs fail late, in animal testing or clinical testing, after significant investment in development. Clearly, improved methods of functional assessment are needed in drug discovery, as well as in other fields such as environmental health and industrial safety. Efficacy and toxicity studies are carried out at several points during drug development including cell-based assays, ADME animal studies and clinical trials. Improvements in the reliability of tissue analysis are expected to improve the reliability and safety of drug testing.
- Personalized medicine: Genomics and proteomics have laid the groundwork for diagnostic and therapeutic treatments that are customized for each individual patient. This personalized medicine is based on a systems approach to disease which takes into account a profile of the whole patient, to determine the most effective therapy [2]. The molecular information derived from genomics and proteomics, and in particular those genes and proteins that have been correlated with particular disease conditions, often referred to as biomarkers, is certainly a valuable source of patient data, but the customization of the treatments will still be limited to well characterized classes of biomarkers, since therapies cannot be tested for every individual genome.
- Environmental Toxicology: The challenge in environmental toxicology is to assess the impact of a growing list of natural and man-made substances on human health. Several factors complicate the problem: increasing large numbers of substances must be tested; the complexities of environmental exposure require testing over a broad range of exposure mechanism, concentration and time; and uncertainties regarding the influence of age and genetic variability on the results. Reliable means to improve the efficiency of testing and evaluation are actively being sought by the National Toxicology Program at the National Institutes of Health.
- Biomedical research: Cell analysis is routinely used in basic biological research as well as in medical research. In both cases the cell analysis is usually focused on a single cellular process, as there are limited tools available for analyzing complex, multi-component system responses.
- Systems biology is an emerging research field focused on the interactions between system components and pathways.
- Functional Assessment: In vivo toxicology measures acute and chronic toxicity in several areas including mutagenicity, organ cytotoxicity, immunotoxicity, neurotoxicity, teratogenicity, and safety pharmacology. In vitro toxicology assays, such as CYP450 induction, Ames test, MTT assay and others, are used to measure these functional responses. In vitro toxicology assays are typically cell based assays which use a variety of cell types including hepatocytes, cardiomyocytes, and others.
- Toxicogenomics uses a combination of traditional genetics and toxicology to identify patterns of gene expression that are associated with toxic effects. Toxicogenomics profiles typically include information such as nucleotide sequences, gene expression levels, protein synthesis, protein function and some phenotypic responses. One goal of toxicogenomics is to identify a sequence of genomic events that lead to a toxic biological response. [13].
- Cell-Based Assays of Cytotoxicity: Existing cell based assays of cytotoxicity are designed to detect a specific endpoint in a population of cells. Examples include trypan blue staining, in which cell death is assessed microscopically by measuring the uptake of trypan blue dye that is excluded by live cells. Other vital stains and fluorescent DNA-binding dyes which are also excluded from live cells can also be used. In another assay format, live cells are labeled with a probe which is released upon cell death. Toxicity can also be assessed by measuring specific cellular functions. One of the more common assays is the MTT assay, where cell proliferation is measured by the activity of a mitochondrial enzyme. Other assays measure specific cellular markers. Examples include measurement of the activation of markers associated with the inflammation such as PGE-2, TNFα, IL1b and other interleukins. Assay formats can be in live cells, fixed cells or cell extracts. Many of the same biomarkers used in these assays will be useful as components of a panel of tissue based cellular biomarkers.
- Metabolism: Drug effect on metabolism is measured by radioactive precursor uptake, thymidine, uridine (or uracil for bacteria), and amino acid, into DNA, RNA and proteins. Carbohydrate or lipid synthesis is similarly measured using suitable precursors. Turnover of nucleic acid or protein, or the degradation of specific cell components, is measured by prelabeling (or pulse labeling) followed by a purification step and quantitation of remaining label or sometimes by measurement of chemical amounts of the component. Energy source metabolism is also analyzed for optimal cell growth.
- Light microscopy shows the general state of cells, and combined with trypan blue exclusion, the percent of viable cells. Small, optically dense cells indicate necrosis, while bloated “blasting” cells with blebs indicate apoptosis. Phase microscopy views cells in indirect light; the reflected light shows more detail, particularly intracellular structures. Fluorescence microscopy detects individual components in cells, after labeling with selective dyes or specific antibodies, and can be used to identify cellular features associated with metabolic states.
- High Content Screening: High Content Screening (HCS) was developed as a method whereby one or more cellular features are measured and analyzed in arrays of cells to identify a cellular functional response [5, 14, 15]. For example, an HCS assay might be used to measure the activation of a particular receptor [16], mitochondrial activity [17], the onset of apoptosis [5, 18], or another cellular function.
- Each of these cellular features represents a measurement of particular cellular component. In some HCS assays a single cellular feature is sufficient to indicate a single cellular function or response. In other cases, the measurement of several features is required to specifically indicate a cellular response. For example, a commercial apoptosis assay uses four cell features to more specifically indicate apoptosis. These features are interpreted based on the knowledge of the biology of apoptosis.
- Multiparameter cytotoxicity assays have been developed by nearly all vendors of HCS technologies. These assays are typically two to four parameter assays which measure cellular features related to cell death, either by necrosis or apoptosis. These assays have been applied in drug discovery, and testing for environmental agents of biowarfare [19] on cultured cells and primary cell preparations. Many of the biomarkers used in HCS can also be used in combinations as components of a feature vector of cellular states in tissue sections and other tissue specimens.
- Reagent Technologies: Multiple reagent technologies are available to assay cellular functions. Fluorescent reagent technologies have matured over the last two decades, with probes available to label subcompartments, localize proteins, label membranes, respond to membrane potentials, sense the local chemical environment, read out molecular mobility, and provide many other measurements [20]. Coupled with antibodies, immunofluorescence labeling provides an easy method for detecting and localizing proteins or protein variants such as phosphorylated proteins. Cells can be engineered to express proteins tagged with any of the color variants of fluorescent proteins [21, 22], and these fluorescent proteins can be further engineered to create biosensors, indicators of specific cellular functions [16, 23-25]. A variety of labels can be combined in a single sample preparation to provide for the measurement of many features in each individual cell in a population, as well as in the population as a whole [10, 26]. Quantum dots, with their single excitation wavelength and narrow emission bands, provide the potential for even higher degrees of multiplexing within an assay [27]. In addition the rainbow of fluorescent probes, there are a number of bioluminescent and chemiluminescent reagents that can be effectively used in cell based assays [28, 29].
- Multiparameter High Content Screening Profiles: A recent comparison of the performance of a panel of cytotoxicity assays, including DNA synthesis, protein synthesis, glutathione depletion, superoxide induction, Caspase-3 induction, membrane integrity and cell viability found that these assays on average had only half the predictive power of animal studies [11]. In contrast, a relatively simple four parameter high content screening assay using human hepatocytes was found to be more predictive than animal-based toxicity assays (O'Brien, P. J.; Irwin, W.; Diaz, D.; Howard-Cofield, E.; Krejsa, C. M.; Slaughter, M. R.; Gao, B.; Kaludercic, N.; Angeline, A.; Bernardi, P.; Brain, P.; Hougham, C., High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580-604 (2006)).
- However, these assays were carried out independently, analyzed only for lowest active concentration, and no attempt was made to combine the readouts in any quantitative way, to improve the overall predictivity. Several studies have shown that the multidimensional cellular responses from cell-based assays can be clustered using standard methods, to identify compounds with similar activities [10, 30, 31]. These studies have demonstrated proof of principle for clustering compound responses, but have not attempted to correlate these identified clusters with specific response profiles and then use the response to predict the physiological impact of unknown substances. Similarly, multidimensional characterization of cellular states in tissue or other specimens can be used to identify patterns of cellular states that are associated with specific disease conditions or patient responses to treatment.
- Classification Tools: A simple automated classifier has been developed for use with some commercially available assays. This classifier allows the use of Boolean operations to combine the outputs from several assay features into a single result [32]. These Boolean operations allow the assay developer to define an output that combines several feature measurements. This is useful in expanding the scope of some HCS assays, but has limited features, and is certainly not designed for, nor would it be easy to use with multidimensional feature sets.
- Multiplexed Fluorescence for Cellular Systems Biology Profiling of Patient Tissue Samples: The invention described herein is an improved method for characterizing patient tissue specimens based on the integration of specific fluorescence labeling technologies with image acquisition and image analysis to create tissue marker profiles. The invention also discloses the use of the profiles to classify tissue specimens for the purposes of identifying patient medical conditions, such as tumor staging and other disease states, as well as response to treatment.
- One aspect of this invention is the integration of the use of traditional histological staining and transmitted light-based imaging with panels of molecularly specific, fluorescently labeled biomarkers to correlate morphometric interpretations with biomarker multiplexing in a “cellular systems biology profile.” The outcome is a powerful machine-learning platform where the instrument is fast and the software is simple.
- A number of instruments are available for transmitted light imaging of tissue sections. For example, the Hamamatsu (Bridgewater, N.J.) NanoZoomer instrument allows automated processing of many slides per day. A number of instruments are available for fluorescent imaging of slides, including confocal microscope, wide-field imaging, and HCS systems. Both wide-field imaging systems and HCS systems can further make use of software deconvolution or structured illumination methods to improve resolution of features in the sections. Therefore, both traditional and more powerful, molecularly specific fluorescent reporters can be imaged in tissue sections on slides or in microplates.
-
FIG. 3 illustrates the relationships between Systems Biology, Cellular systems biology, cellomics, Genomics, Proteomics and Metabolomics. Systems biology is the study of an organism, viewed as an integrated and interacting network of components, starting with genes, proteins, and biochemical pathways, that give rise to life. Because biological systems are complex, emergent properties result from interactions between system components. These emergent properties are properties that are not predicted from component properties, but are the result of interactions between components, and therefore require a systems approach to measurement and analysis. - Cellular systems biology is the study of the cell as the basic unit of life: an integrated and interacting network of genes, proteins and biochemical reactions which give rise to functions and life. The cell is the simplest functional biological system, and therefore an ideal system from which to extract knowledge about biological systems. Cellular systems biology involves the application of cellular analysis technologies to the understanding of how the interactions of cellular components gives rise to the complex biochemical and molecular processes that contribute to cell functions. These cell functions include complex behavioral responses of cells to environmental changes as well as experimental treatments. As illustrated in
FIG. 3 Cellular systems biology is a component of Systems Biology. - The present invention relates to a method for identifying biological conditions in higher level organisms, including humans, from “systems-based” panel or panels of measurements of cellular and/or tissue features in tissue preparations, including blood, including sections, smears and other cellular tissue preparations. The “systems-based” panel of measurements within the same samples dramatically extends the present methodology that focuses on individual or a few parameters to the measurement and subsequent analysis of the systems response profile from the tissue investigated. The methods of this invention also provide a means to quantify the similarity of biological states and predicted modes of action based on the tissue system profiles. There are many applications which will benefit from the use of this invention, including animal testing in drug discovery and environmental health, medical diagnostics and human clinical trials. Application of this technology will improve the efficiency and reduce the cost of drug development. The invention will also improve the efficiency of environmental toxicology testing.
- The invention includes various embodiments such as protocols, reagent panels, databases and informatics software.
-
FIG. 5 illustrates an example of an embodiment of the invention which comprises a panel of assay function classes used to profile toxicity. These function classes include Stress Pathways, Organelle Function, Cell Cycle Stage, Morphology Changes, Apoptosis and DNA Damage. Other function classes can be used in toxicity assessment and other functional applications of this method, as will be appreciated by a person of skill in the art. The methods of this invention can be used to validate additional assays and function classes which can be added to a profile to improve the sensitivity, specificity or range of applicability of a specific embodiment of this invention. - Within each of these assay function classes, one or more assays are selected to be used to measure one or more cellular systems biology features of cells within a tissue as an indication of a response in that assay function class. To illustrate how cellular systems biology feature measurements can be made on cells or tissues, a similar high content screening assay with multiple features for cells in arrays is illustrated in
FIG. 6 . In this example assay, representative images from each channel of a multiplexed high content screen are shown. Algorithms are used to extract information from the images to produce outputs of at least four different cell features including nuclear size and shape, cell cycle distribution, DNA degradation, the state of the microtubule cytoskeleton, the activation state of the tumor suppressor p53, and the phosphorylation state of histone H3, a protein involved in the regulation of the cell cycle. Assays can be combined in two or more assay plates to produce a compound profile with six or more features. Assays such as this, which include image analysis algorithms with multiple output features are available from a variety of commercial sources, especially HCS technology vendors such as Cellomics (Pittsburgh, Pa.), GE Healthcare (Piscataway, N.J.), Molecular Devices (Sunnyvale, Calif.), and others, and can be implemented in any one of the standard image analysis software packages. The output features from the combination of assays, both commercial and custom developed, are combined to form a single response profile. In one embodiment, assays are selected from at least about four of the function classes inFIG. 5 , to provide a sufficiently broad profile for predicting higher level integrated functions. One embodiment of this invention employs a panel of assays with one from each of these function classes. These assays are used first to build a predictive toxicology knowledgebase, and then to generate profiles of test compounds, to compare with the classes in the knowledgebase, and thereby to predict toxic affects of the test substances. Another embodiment of the invention uses all the assays listed inFIG. 5 to produce a more extensive profile, and then uses a statistical method such as principle components analysis to identify the features with the highest predictive power for a selected profile of toxicology parameters. - In some profiles multiple cell types are identified and analyzed to more broadly indicate tissue associated responses. In addition, analyses can include combinations of assays where individual tissue cells are measured, along with higher throughput assays where the population of tissue cells or a region of a tissue section is analyzed as a whole for morphometry, texture, intensity, or other features, as will be appreciated by a person of skill in the art.
-
FIGS. 7 and 8 illustrate a flow diagram for two embodiments of the invention. The procedures inFIGS. 7 and 8 illustrate separate procedures. The procedure inFIG. 7 illustrates the procedure used to populate the tissue profile database and create the classes of response profiles linked to the histological determinations. The procedure inFIG. 8 illustrates the process for using the profile database to predict the classify tissue and identify medical states. The procedure inFIG. 8 comprises the following steps: 1. Tissue samples are prepared on slides or other carriers. 2. The tissues sections are fixed and stained with labels specific to the biomarker of interest. 3. The slides are read on an imaging system, such as an HCS reader, high throughput slide-scan reader, automated microscope or other detector. 4. Assay algorithms are applied to convert raw image data to assay data points. 5. The assay data points are clustered to produce response classes. 6. Responses classes are used to create a response profile for each of the classes. 7. Response profiles are established for the cells in control tissue specimens in each slide set. 8. Response profiles are clustered to identify unique profiles which can be used to classify and predict functional responses. - The procedure illustrated in
FIG. 8 is used to evaluate substances for physiological effects. It comprises a sequence of steps: 1. Samples are prepared on slides or other carriers. 2. The cells are fixed and stained with labels specific to the biomarker of interest. 3. The plates are read on an imaging system, such as an HCS reader, high throughput slide-scan reader, automated microscope or other detector. 4. Assay algorithms are applied to convert raw image data to assay data points. 5. The tissue cell features are classified based on the assay data points. 6. The database is searched for physiological response profiles that match the cellular response profiles. 7. Predictions for physiological responses are made based on similarity of response profiles. 8. A report is generated tabulating the probability of each physiological response based on the substance response data. -
FIG. 7 illustrates the overall sample flow while processing tissue sections to produce cellular systems biology profiles. A slide set comprises two or more tissue sections, each of which is used to collect a cellular systems biology profile. Each tissue section in the set produces an image set of images from one or more fields in each tissue section, at each of the wavelengths to be analyzed. Analysis of the image set produces a set of cellular systems biology features. The cellular systems biology features are processed and clustered to produce a cellular systems biology profiles to go into the data base, or to be used to search the data base to identify probable modes of physiological response or to set priorities for patient stratification. - Populations of cells within tissues can occupy discrete response classes, and move from class to class as a disease or treatment proceeds. In one example cellular systems biology profiles can be built through the application of Kolmogorov-Smirnov (KS) similarity analysis. KS values are one means to characterize a population and provide a measurement that can be used to cluster samples from many patients or other tissue sources. For example, cellular systems biology features based on KS values can be clustered by agglomerative clustering or other clustering methods, to build cellular systems biology profiles that identify tissues with similar cellular systems biology profiles. Other methods in addition to KS analysis can be used to process data prior to clustering, and a variety of clustering algorithms can be usefully applied.
-
FIG. 8 illustrates one embodiment of the invention, wherein the data flow is used to generate response profiles for a panel of tissue samples or tissue assays. Tissue samples from sources with known conditions or medical outcomes are processed to produce cellular response profiles, which are merged with other information on physiological conditions. The combined profiles of each tissue are clustered to identify unique profiles that can be used to distinguish classes of response. The response classes are stored in a database for use in classifying test samples. Test tissue samples are processed to produce cellular response profiles that are then matched to those in the database, and based on the similarity of the response to the database profiles, probabilities are calculated for each of the reference response profiles in the database, producing a similarity profile. - Algorithms: The algorithms, custom designed or encapsulated in the application software provided by HCS vendors, or other imaging software providers, produce multiple numerical feature values (cellular systems biology features) such as subcellular object intensities, shapes, and location for each cell within an optical field. The vHCS™ Discovery Toolbox (Cellomics, Inc), Metamorph (Molecular Devices), software from GE Healthcare and other HCS and image analysis packages can be used to batch analyze images following acquisition. Contingent on the type of tissue sample and its preparation, the total number of cells measured per sample is typically in the range of at least about 100 to at least about 10000, depending on the heterogeneity of the cellular response and the sensitivity of the assay. Examples of assay output parameters illustrate the function of application software. For example, to calculate changes in nuclear morphology, the average nuclear intensity value for each cell can be used. Nuclear condensation produces larger average nuclear intensity values while nuclear enlargement accompanied by DNA degradation produced smaller average nuclear intensity values relative to normal cells. The measurement of histone H3 phosphorylation is obtained using the average nuclear intensity of cells labeled with antibodies specific for phosphohistone H3 as previously reported. Those skilled in the art of imaging and cell analysis will recognize that there are many such algorithms readily available, and that there are many such cellular processes that are amenable to image-based analysis of cells and tissues to measure cellular/tissue functions.
- Clustering and Classification of Responses: To quantify differences in the cellular systems biology feature responses induced in a population of tissue cells, such as healthy tissue, tumor tissue, and other abnormal tissues, several different methods can be effectively used. Within a population of similar cells or collections of cells in tissues, many different individual cellular response profiles are possible, including the well known heterogeneity in cellular responses [33, 34]. In one embodiment, the cellular systems biology feature response distribution for each cell parameter from a tissue section can be compared with that of a control sample using a KS goodness of fit analysis (KS value) [35]. The testing for significant changes in fluorescence-derived histograms is used to calculate KS values for replicate control samples and use these data to set a threshold (e.g., critical value), above which, a cellular systems biology feature response would be considered significant [36].
- To perform significance testing of disease or therapy dependent changes or patient-specific differences in tissue features in multiplexed tissue-derived cell population distribution data, the one-dimensional KS test can be adapted to two dimensions as described by Peacock [37] and further refined by Fasano and Franceschini [38]. The two-dimensional cell population data distributions representing two physiological parameters from a cellular systems biology feature set are compared to the two-dimensional cell population data distributions obtained from multiple specimens. First, each distribution is divided into quadrants defined by the median x and y axis values calculated from the untreated cell data distributions. The two-dimensional KS value was then found by ranging through all four quadrants to find the maximal difference between the fraction of cells in each treated quadrant and the fraction of cells in each corresponding untreated quadrant.
- The heterogeneity of cell populations within tissues can also be analyzed with other statistical methods to evaluate cellular systems biology profiles. In another embodiment of the invention, all the cell feature values from each cell are combined to create a cellular systems biology profile. The cellular systems biology profiles can consist of the actual measured values, and/or the principal components of the measured values, identified by standard methods [39, 40]. The cellular systems biology features from each population of tissue cells and from different samples are clustered using standard methods [39, 40], to produce cellular systems biology profiles. These profiles are used to build a classifier. All the cells in a single tissue sample, and therefore characteristic of the same medical condition, are classified into these response classes. The percent occupation of each of these classes then becomes a population response profile for that sample. In one example, the cellular systems biology profiles from the samples are linked to the cellular systems biology profiles (e.g., toxicity response profiles) from the reference samples and stored in the database. The cellular systems biology profiles from the test samples are classified using a probabilistic classifier based on the cellular systems biology profiles of the reference samples in the database to predict toxicological responses or to stratify patients. Other embodiments use alternative analysis algorithms or methods to cluster cell response profiles and create a classifier based on the known properties of a training set of tissue sections.
- Example of tissue sample profiling of normal, diseased, and treated tissues in humans and animals using liver as a specific tissue example:
- The liver, a gland comprised of a host of cell types, performs both exocrine and endocrine functions that are regulated by exquisitely orchestrated cellular activities. Furthermore, the liver is also responsible for the metabolism of drugs and steroids, many of which target their toxic activities to one or more cell types present in the liver. Other important functions of the liver include deiodination of triiodothyronine and thyroxine, gluconeogenesis and glycogenolysis, maintenance of normal glucose concentration in blood, etherification of free fatty acids into triglycerides, storage of glycogen, fat, and iron, detoxification of poisons and hydrogen peroxide, and hematopoiesis from the second to the eighth month of intrauterine life.
- Thus, a cellular systems biology characterization of cells within the intact structure of the liver provides one of the most relevant profiles of normal or diseased tissue, and the effects that chemical compounds have on the liver as a living system.
- The intact liver, like other glands, is comprised of a stroma and a highly vascularized and innervated parenchyma. Tissue sections of liver will therefore be comprised of several cell types including:
- 1. Squamous epithelial cells and fibroblasts—form part of the stroma
- 2. Nerve fibers—cellular processes that accompany blood vessels to innervate the parenchyma
- 3. Capillary endothelium—cells forming the walls of blood vessels
- 4. Kupfer cells—specialized macrophages
- 5. Fat cells—store triglycerides
- 6. Blood cells—cells that include erythrocytes, immune cells, and platelets
- 7. Hepatocytes—the most prevalent cell type in the liver. Hepatocytes perform most of the functions of the liver listed above.
- Rationale for combining traditional transmitted light microscopy and multiplexed fluorescence based cytology of tumor sections: 1. Pathologists directly involved in test. 2. Allows direct comparison with present visual inspection of H&E stained sections as well as sections labeled with other manually detectable histochemical stains. 3. Maintains tissue organization and permits analysis of penetrating immune cells. 4. Allows implementation of automated imaging quantitation of the system. 5. Allows correlation of the presence and state of activation of the migratory immune cells with the presence and state of activation of the immune cells in the lymph nodes and peripheral blood. 6. Tissue toxicity profiles can be produced from either/or tissue-based profiles or peripheral blood profiles based on the tissue-based profile data. 7. The multiplexed, fluorescence-based biomarkers can be a combination of specific reagents to detect specific proteins and post-translational modifications of the proteins, specific RNA species including coding or non-coding RNA's, and micro-RNA's.
- Below is a list of biomarkers that can be combined in various combinations to profile the systems response of liver tissue to disease or compound treatment:
- 1. Metabolism biomarkers:
-
- Cytochrome P450 isotypes—expression levels and isotype ratios in hepatocytes.
- P-glycoprotein activity—expression level of a membrane-bound protein that pumps multiple compound substrates out of a cell, especially hepatocytes.
- 2. DNA damage biomarkers:
-
- Cell cycle regulation—The distribution of the total DNA content within the nucleus of a cell contained within a tissue slice can be determined using a nuclear label such as Hoechst 33342, Draq-5, or propidium iodide.
- Nuclear morphology and chromatin condensation—Nuclear damage can sometimes be correlated with a change in nuclear morphology or the condensation state of the chromatin. The morphology (e.g., shape and size) or the structure of the chromatin (brightness per unit area) of a nucleus contained within a tissue slice can be determined using a nuclear label such as Hoechst 33342, Draq-5, or propidium iodide.
- 8-oxoguanine—Oxidative damage to DNA often generates an oxidized analog of guanine Increased 8-oxoguanine signals that the DNA in a cell has been damaged.
- Activation of DNA repair proteins (APE/ref-1)—The DNA in hepatocytes or any other cells present in liver that contain DNA are susceptible to damage due to disease or compound treatment. Changes in the expression level of APE/ref-1 signals that the DNA damage response mechanism has been activated within a cell.
- Histone H2A.X phosphorylation—The DNA in hepatocytes or any other cells present in liver that contain DNA are susceptible to damage due to disease or compound treatment. Phosphorylation of histone H2A.X signals that the DNA damage response mechanism has been activated within a cell.
- p53 protein activation.
- Rb protein phosphorylation
- 3. Cell morphology and differentiation biomarkers:
-
- Cell spreading and hypertrophy
- Cell-cell or cell-stroma adhesion
- Angiogenesis of new vessels
- Remodeling of innervating nerve fibers
- 4. Stress-induced transcription factor activation or inhibition biomarkers:
-
- NF-B
- ATF-2
- CREB
- AP-1
- MSK
- NFAT
- Stat1, 2, 3
- Oct-1
- 5. Changes in phosphorylation state of stress kinases biomarkers:
-
- ERK
- JNK
- p38
- RSK90
- MEK
- 6. Induction of apoptosis or necrosis biomarkers:
-
- DNA content and degradation
- Nuclear morphology
- Caspase activation (multiple subtypes)
- Mitochondrial function (mass-potential)
- Bax mitochondrial translocation
- Cytochrome c mitochondrial release
- PARP activation
- 7. Remodeling of the cytoskeleton biomarkers:
-
- Actin cytoskeleton stability
- Microtubule cytoskeleton stability
- 8. Organelle morphology biomarkers:
-
- Mitochondrial size, number, and shape
- Golgi size and localization
- Peroxisome size and number
- Glycogen particle size and number
- Lysosome size and number
- Lipid droplet size and number
- Endoplasmic reticulum shape and localization
- Tight junction number and localization
- 9. Immune cell presence and activity biomarkers:
-
- The percentage and ratios of specific migratory immune cells in hepatocytes, lymph system, and blood supply.
- Phenotypes of key immune cell types in liver cancer tissues that reflect either an anti-tumor or tumor-supporting function.
- Apoptosis of immune cells
- Expression of death receptor ligands such as TRAIL
- Expression of biomarkers associated with immune cell dysfunction such as PD1 in lymphocytes
- NK and LAK cell activity to characterize anti-tumor surveillance
- Example of tissue preparation: In one embodiment, a small animal such as a mouse or a rat is treated with one or more test compounds for various lengths of time (1 min to 21 d). In another embodiment, a small animal model of disease including metabolic models such as diabetes, cancer, or other models that either directly or indirectly involve the liver will be used. In yet another embodiment, human liver tissue from diseased or compound treated patients will be used. Normal, diseased, and treated tissue samples will be prepared. Tissue samples will be processed as either frozen sections or formaldehyde fixed paraffin-embedded sections. In addition, tissue samples will also be obtained for gene expression analysis.
- For clarity, other major tissue types will be treated the same way. Panels of biomarkers of both a general cell responses and responses more tissue-specific will be produced and applied.
- The optimal combination (multiplexing) of the liver tissue biomarkers, will be the key to creating an optimal cellular systems biology profile of the tissue. The optimal number of number of multiplexed biomarkers will range from about four to about twelve biomarkers. Normal, diseased, and treated tissue samples will be prepared. Tissue samples will be processed as either frozen sections or formaldehyde fixed paraffin-embedded sections. In addition, tissue samples will also be obtained for gene expression analysis.
- 1. Below is an example of liver tissue analysis:
- a. Gene expression profiling is performed that compares “normal” liver tissue with tissues from diseased or compound treated animals.
- b. Gene expression informatics—Gene expression profiles analyzed by informatics tools to characterize gene expression as a function of disease or compound treatment to identify gene products.
- c. Gene products prioritized based on known reference points from normal liver tissue and then antibodies acquired or produced to create test panels.
- 2. Combinations of histological stains and key biomarkers multiplexed for fluorescence-based immunocytochemistry of the “functional biomarkers”:
- a. Multiple 5 μm sections prepared from liver tissue. The first section labeled with H&E or other histological stain for traditional pathological analysis. The successive sections processed for multiplexed, fluorescence-based cytometry.
- b. In addition to the panels of potential biomarkers based on the gene expression profiling, some sections will be labeled with multiplexed panels of antibodies to key migratory immune cells; including lymphocytes (e.g. CD3 and CD8). The level of immune cell activation, concentration and organization will be an important element of the profile.
- Example biomarker combinations to profile liver tissues: In one embodiment, liver tissue slices are labeled for two or more biomarkers to profile differences between non-diseased and diseased or non-treated and treated animals. Biomarkers of a wide range of tissue functions are preferable since they provide breadth to the systems profile of the tissue. The number of biomarkers in one embodiment is about four to about ten biomarkers, and multiple biomarkers can be labeled in the same tissue section. This permits the comparison of some biomarker activities within the same cells.
- In one example, a rat is treated with an apoptosis-inducing compound such as paclitaxel or camptothecin for times ranging from about 30 min to about 21 d using multiple doses in the range from about 1 μg/kg up to about 100 mg/kg. After treatment, the animal is sacrificed and the liver tissue either frozen and sectioned or fixed with a chemical such as formaldehyde and then impregnated with paraffin using standard methods before sectioning. A hematoxylin and eosin (H&E) stain can then be performed on one or more sections to provide a sample for traditional, transmitted light-based pathology interpretation. Other sequential sections can be labeled with combinations of fluorescent immunoreagents and physiological indicator dyes for image-based analysis, for example:
-
Sequential Section # 1 - 1. Hoechst 33342 to label the nuclei and provide measurements of nuclear morphology, cell cycle regulation, and chromatin condensation.
- 2. Anti-phospho-histone H2A.X as a biomarker of oxidative DNA damage
- 3. Anti-p53 as a biomarker of the DNA damage response.
- 4. Anti-phospho-c-jun as a biomarker of stress kinase induction.
-
Sequential Section # 2 - 1. Hoechst 33342
- 2. Anti-cytochrome c as a biomarker of mitochondrial number, size and shape.
- 3. Anti-alpha-tubulin as a biomarker of microtubule cytoskeletal remodeling.
- 4. Fluorescently labeled phalloidin as a biomarker of actin cytoskeletal remodeling.
-
Sequential Section # 3 - 1. Hoechst 33342
- 2. Anti-phospho-retinoblastoma protein as a biomarker of cell cycle checkpoint activity.
- 3. Anti-NF-kappa-B as a biomarker of inflammation-related cell signaling.
- 4. Anti-CD3 as a biomarker of lymphocyte infiltration into the tissue.
-
Sequential Section # 4 - 1. Hoechst 33342
- 2. Anti-activated-
caspase 3 as a biomarker of apoptosis. - 3. Anti-PMP70 as a biomarker of peroxisome size and number.
- 4. Anti-cytochrome P450 as a biomarker of hepatocyte metabolic activity.
- Example of Patient Sample Profiling for Breast Cancer: Cancer is a systems biology disease that requires a systems biology approach to create better stratification of individual patients for better diagnostics and treatments. Cancer is also an inflammatory process that involves the full range of the immune response. Therefore, tumors contain a combination of cancer cells at different stages of evolution, normal cells and an infiltration of the migratory immune cells such as dendritic cells, macrophages and lymphocytes. Tumor “cellular systems biology” characterization should therefore be a combination of tumor cell biomarkers and immune cell biomarkers. A key to tumor cellular systems biology is the use of a multiplexed panel of tumor biomarkers for cancer cells and immune cells that will better stratify patients. In addition, correlations with lymph nodes and peripheral blood cell analysis would determine if circulating immune cells carry tumor specific information that could create a very simple blood cell test. The number, type and level of activation of migratory immune cells in the blood could also become a “window” on the tumor itself.
- Rationale for Combining Traditional Transmitted Light Microscopy and Multiplexed Fluorescence-Based Cytology of Tumor Sections: 1. Pathologists directly involved in test. 2. Allows direct correlation with present visual inspection of H&E stained sections and staging tumors by morphometric analyses. 3. Builds on the success of Her2/Neu as a single “functional protein” biomarker, but which also only identifies a small sub-set of patients. 4. Maintains tissue organization and permits analysis of penetrating immune cells. 5. Enables the development of a “systems” profile of the tumor including multiplexed breast cancer biomarkers and migratory immune cell presence and state of activation. 6. Allows implementation of automated imaging quantitation of the system. 7. Allows correlation of the presence and state of activation of the migratory immune cells with the presence and state of activation of the immune cells in the lymph nodes and peripheral blood. 8. Stratification and diagnostic tests can be produced from either/or tissue-based profiles or peripheral blood profiles based on the tissue-based profile data. 9. The multiplexed, fluorescence-based biomarkers can be a combination of specific reagents to detect specific proteins and post-translational modifications of the proteins, specific RNA species, including micro-RNA's either coding or non-coding in cells.
- Measurement of specific protein expression and state of activation, as well as the presence of specific micro RNA's within cells and tissues are key “functional” read-outs. The expression of a gene is only one element of the systems biology and the present genomic tests are only correlations of gene expression without any functional information. Cellular functions are carried out primarily by proteins whose expression level, cellular localization and post-translational modification are responsible for carrying out normal and abnormal functions. Specific microRNA's have also been shown to be disease specific and are critical in regulating gene expression, similar to regulatory proteins. In addition, tumors are systems in that they are a complex integration of normal cells, a range of genetically evolving cancer cells and migrating immune cells. Therefore, a cellular systems biology profile of multiple protein and/or micro RNA biomarkers is important.
- Background on the Importance of the Immune System in Breast Cancer: The immune system becomes dysfunctional early in the process of cancer occurrence and continues throughout the evolution of the cancer stages leading to metastatic disease. The migratory immune cells are attracted to the growing tumors by pro-inflammatory cytokines and chemotactic factors. Tumor infiltrating lymphocytes release growth factors and cytokines that actually promote growth of the tumors, while the anti-tumor functions are weak or non-existent. Dendritic cells and tumor-associated macrophages present in the tumor exhibit phenotypes that demonstrate a supporting role for tumor growth. Regulatory T cells accumulate in the tumors, as well as in the tumor-draining lymph nodes and peripheral blood of patients. These latter cells actually protect tumor cells as part of the “recognition of self” immune process. Therefore, the immune system is mostly a tumor-promoting system and supports the progression and metastasis in most cancers.
- Gene expression fingerprints from tumor samples have been used to distinguish subtypes of breast cancers and to assign some prognostic index. These gene expression profiles usually identify genetic profile “signatures” indicative of the infiltration of the migratory immune cells. Unfortunately, in methods such as gene expression profiling, the disaggregated tumor samples the “tumor as a system” is lost since the whole tissue architecture and tumor cell-migratory immune cell structural relationships are lost.
- Tissue sections, including tissue micro-arrays (TMA's) used in patient stratification and diagnostic tests are valuable, since the tumor “system” can be analyzed and quantified through the integrated use of traditional transmitted light stains that are standard in pathology and oncology with multiplexed fluorescence-based biomarkers of more functional parameters of both the migratory immune cells and the cancer cells. Therefore, the traditional information from pathology can be combined with panels of biomarkers using multiplexed fluorescence.
- In addition to the primary tumors, the tumor-draining and non-sentinel lymph nodes are important sites of tumor and immune system interactions that could aid in the “functional cellular systems biology signature”. For example, the presence of tumor cells in the tumor-draining lymph nodes affects the types and numbers of immune cells within the nodes. Furthermore, the non-sentinel auxiliary nodes can also be influenced by local tumor growth, since it has been shown that CD4 T cells and dendritic cell counts have been used to predict survival in breast cancer patients. Also, it is clear that tumor progression also can be observed in the peripheral immune system by analysis of the circulating leukocytes, circulating T cells and other immune cells. Therefore, a correlative analysis of the patient's circulating immune cells in the peripheral blood with the tumor “system”, as well as lymph node “system” will create the an excellent opportunity to create powerful tests in tumors, lymph nodes and blood.
- Below is a list of biomarkers that can be combined in various combinations for optimal staging and diagnostic for breast cancer (in one embodiment, the combination of cancer cell and immune biomarkers may be most suitable):
- Examples of Cancer Cell Biomarkers:
-
- Her2/Neu Protein (now used as single biomarker)
- Estrogen Receptor Protein (ER)
- Ki-67
- Cox-2
- P16
- A growing number of key proteins or post-translational modifications of proteins correlated with a cancer process
- A growing number of micro RNA's correlated with specific cancers
- Examples of Immune Biomarkers:
-
- The percentage and ratios of specific migratory immune cells in tumors, tumor draining lymph nodes, non-sentinel lymph nodes and peripheral blood
- Phenotypes of key immune cell types in breast cancer patients that reflect either an anti-tumor or tumor-supporting function
- Apoptosis of immune cells
- Expression of death receptor ligands such as TRAIL
- Expression of biomarkers associated with immune cell dysfunction such as PD1 in Tumor Infiltrating Lymphocytes.
- NK and LAK cell activity to characterize anti-tumor surveillance
- The optimal combination (also referred to herein as multiplexing) of the cancer cell and immune biomarkers, especially in the tumors, will be the determinative to creating an optimal cellular systems biology profile of the patient. In one embodiment, the optimal number of number of multiplexed biomarkers is in the range from about four to about twelve biomarkers.
- Technical Steps: Normal and breast cancer positive patient materials will be prepared. Patient tumor samples will be processed as either frozen sections or formaldehyde fixed paraffin-embedded sections. Furthermore, lymph node samples will be treated the same as the primary tumors. In addition, samples will be obtained from the tumors for gene expression analysis. Migratory immune cells will also be separated from the blood samples for both flow cytometry and image cytometry. Below is an outline of steps in one method of the invention:
- 1. Patient Tumor Sample-Gene Expression Profiling comparing “normal” tissue with patient tumors staged in the traditional manner.
- 2. Gene Expression Informatics-Gene Expression Profiles analyzed by informatics tools to characterize gene expression as a function of stage of breast cancer and to identify gene products (use Her2/Neu as reference).
- 3. Gene products prioritized based on known reference points including Her2/Neu and then antibodies acquired or produced to create test panels.
- 4. Combinations of selected cancer cell biomarkers multiplexed for fluorescence-based immunohistochemistry.
- 5. Multiple 5 micron tissue sections prepared from tumor samples. The first section labeled for H&E for traditional staging by a pathologist. The successive sections processed for multiplexed, fluorescence-based cytometry.
- 6. In addition to the panels of potential cancer cell biomarkers based on the gene expression profiling, some sections will be labeled with multiplexed panels of antibodies to key migratory immune cells; including lymphocytes (e.g., CD3 and/or CD8). The level of immune cell activation, concentration and organization will be an important element of the profile.
- The percentage and ratios of specific migratory immune cells in tumors, tumor draining lymph nodes, non-sentinel lymph nodes and peripheral blood will be calculated and used build cellular systems biology profiles. Example percentage ranges of immune cells in tissues are as follows:
- Lymphocytes: 1%-90% (distinct sub-types within this percentage)
- Neutrophils: 1%-90%
- Eosinophils: 0.01%-50%
- Monocytes: 0.01%-50% (distinct sub-types within this percentage)
- Example ranges of ratios of immune cells in tissues for cellular systems biology profiling:
- T-cell lymphocyte subtype I/T-cell lymphocyte subtype II: 0.01-1000
- T-cell lymphocytes/B-cell lymphocytes: 0.1-1000
- Dendritic cells/lymphocytes: 0.01-1000
- Macrophages/lymphocytes: 0.01-1000
- Lymphocyte sub-set/lymphocyte sub-set: 0.01-1000
- The optimal combination of biomarkers that suitably stratify patient samples from stage I to stage IV will be selected for profiling on new patients. New patients will allow the direct correlation of peripheral immune cells with the tumor tissue and lymph node sections.
- Example of profiling brain tissue for biomarkers of Alzheimer's disease:
- In this embodiment, human brain tissue is obtained, fixed, and sectioned. A subset of sections are labeled with one or more stains to visualize morphological structures within the tissue associated with the pathology of Alzheimer's disease. In one example, a silver-based stain is used to visualize hallmarks of Alzheimer's disease such as neurite plaques and neurons with neurofibrillary tangles [41]. Analysis of the silver-stained tissue from multiple patients before, during, or after treatments with drugs provides data which are then entered into a profile.
- In a second embodiment, another subset of the same tissue sections from the same patient is reacted with reagents to label two or more biomarkers in either the same tissue section or in contiguous serial sections from the same tissue sample. Example biomarkers that can be labeled using immunofluorescence approaches include A 42, A 40, von Willebrand factor, and the microtubule binding protein tau [42]. Other biomarkers are also possible. These include phosphorylated APP (amyloid precursor protein) and unphosphorylated APP. Furthermore, biomarkers of other cellular processes can be included in the profile. Profiles built from multiple biomarker labels measured within tissues from a single patient or profiles built from biomarker labels measured in multiple patient tissue samples are clustered to identify unique profiles that can be used to classify and predict possible patient outcomes, or functional responses to drug treatments, or a combination of both.
-
- 1. Hood, L. and R. M. Perlmutter, The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol, 2004. 22(10): p. 1215-7.
- 2. Hood, L., et al., Systems biology and new technologies enable predictive and preventative medicine. Science, 2004. 306(5696): p. 640-3.
- 3. Taylor, D. L., et al., Potential of machine-vision light microscopy in toxicologic pathology. Toxicol Pathol, 1994. 22(2): p. 145-59.
- 4. Schroeder, K. S. and B. D. Neagle, FLIPR: A New Instrument for Accurate, High Throughput Optical Screening. J Biomol Screen, 1996. 1(2): p. 75-80.
- 5. Giuliano, K. A., et al., High-Content Screening: A New Approach to Easing Key Bottlenecks in the Drug Discovery Process. J Biomol Screen, 1997. 2(4): p. 249-259.
- 6. Dow, A., S. A. Shafer, and A. S. Waggoner. Morphological segmentation of multiprobe fluorescence images for immunophenotyping in melanoma tissue sections. in Intelligent Robots and Computer Vision XII: Algorithms and Techniques. 1993: SPIE.
- 7. Dow, A. I., et al., Automatic multiparameter fluorescence imaging for determining lymphocyte phenotype and activation status in melanoma tissue sections. Cytometry, 1996. 25(1): p. 71-81.
- 8. Galbraith, W., et al., Imaging cytometry by multiparameter fluorescence. Cytometry, 1991. 12(7): p. 579-96.
- 9. Camp, R. L., G. G. Chung, and D. L. Rimm, Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med, 2002. 8(11): p. 1323.
- 10. Taylor, D. and K. Giuliano, Mutiplexed high content screening assays create a cellular systems biology approach to drug discovery. Drug Discov Today, 2005. 2(2): p. 149-154.
- 11. Xu, J. J., D. Diaz, and P. J. O'Brien, Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact, 2004. 150(1): p. 115-28.
- 12. Perlman, Z. E., T. J. Mitchison, and T. U. Mayer, High-Content Screening and Profiling of Drug Activity in an Automated Centrosome-Duplication Assay. Chembiochem, 2005. 6(2): p. 218.
- 13. Lee, K. M., J. H. Kim, and D. Kang, Design issues in toxicogenomics using DNA microarray experiment. Toxicol Appl Pharmacol, 2005.
- 14. Abraham, V. C., D. L. Taylor, and J. R. Haskins, High content screening applied to large-scale cell biology. Trends Biotechnol, 2004. 22(1): p. 15-22.
- 15. Giuliano, K. A., J. R. Haskins, and D. L. Taylor, Advances in high content screening for drug discovery. Assay Drug Dev Technol, 2003. 1(4): p. 565-77.
- 16. Conway, B. R. and K. T. Demarest, The use of biosensors to study GPCR function: applications for high-content screening. Receptors Channels, 2002. 8(5-6): p. 331-41.
- 17. Woollacott, A. J. and P. B. Simpson, High Throughput Fluorescence Assays for the Measurement of Mitochondrial Activity in Intact Human Neuroblastoma Cells. J Biomol Screen, 2001. 6(6): p. 413-420.
- 18. Lovborg, H., P. Nygren, and R. Larsson, Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol Cancer Ther, 2004. 3(5): p. 521-6.
- 19. Tencza, S. B. and M. A. Sipe, Detection and classification of threat agents via high-content assays of mammalian cells. J Appl Toxicol, 2004. 24(5): p. 371-7.
- 20. Waggoner, A., Fluorescence probes for analysis of cell structure, function and health by flow and imaging cytometry., in Applications of Fluorescence in the Biomedical Sciences, D. Taylor, et al., Editors. 1986, Alan R. Liss, Inc.: New York. p. 3-28.
- 21. Chalfie, M., et al., Green fluorescent protein as a marker for gene expression. Science, 1994. 263(5148): p. 802-5.
- 22. Chudakov, D. M., S. Lukyanov, and K. A. Lukyanov, Fluorescent proteins as a toolkit for in vivo imaging. Trends Biotechnol, 2005. 23(12): p. 605-13.
- 23. Umezawa, Y., Genetically encoded optical probes for imaging cellular signaling pathways. Biosens Bioelectron, 2005. 20(12): p. 2504-11.
- 24. Giuliano, K. A. and D. L. Taylor, Fluorescent-protein biosensors: new tools for drug discovery. Trends Biotechnol, 1998. 16(3): p. 135-40.
- 25. Giuliano, K. A. and D. L. Taylor, Measurement and manipulation of cytoskeletal dynamics in living cells. Curr Opin Cell Biol, 1995. 7(1): p. 4-12.
- 26. Zhang, S., C. Ma, and M. Chalfie, Combinatorial marking of cells and organelles with reconstituted fluorescent proteins. Cell, 2004. 119(1): p. 137-44.
- 27. Michalet, X., et al., Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 2005. 307(5709): p. 538-44.
- 28. Hemmila, I. and V. Laitala, Progress in lanthanides as luminescent probes. J Fluoresc, 2005. 15(4): p. 529-42.
- 29. Roda, A., et al., Biotechnological applications of bioluminescence and chemiluminescence. Trends Biotechnol, 2004. 22(6): p. 295-303.
- 30. Mitchison, T. J., Small-molecule screening and profiling by using automated microscopy. Chembiochem, 2005. 6(1): p. 33-9.
- 31. Perlman, Z. E., et al., Multidimensional drug profiling by automated microscopy. Science, 2004. 306(5699): p. 1194-8.
- 32. Abraham, V. C., et al., Automated Classification of Individual Cellular Responses Across Multiple Targets. Preclinica, 2004. 2(5): p. 349-355.
- 33. Rubin, H., Early origin and pervasiveness of cellular heterogeneity in some malignant transformations. Proc Natl Acad Sci USA, 1984. 81(16): p. 5121-5.
- 34. Elsasser, W. M., Outline of a theory of cellular heterogeneity. Proc Natl Acad Sci USA, 1984. 81(16): p. 5126-9.
- 35. Giuliano, K. A., et al., Systems cell biology knowledge created from high content screening. Assay Drug Dev Technol, 2005. 3(5): p. 501-14.
- 36. Giuliano, K. A., Y.-T. Chen, and D. L. Taylor, High-Content Screening with siRNA Optimizes a Cell Biological Approach to Drug Discovery: Defining the Role of P53 Activation in the Cellular Response to Anticancer Drugs. J Biomol Screen, 2004. 9(7): p. 557-568.
- 37. Peacock, J. A., Two-dimensional goodness-of-fit testing in astronomy. Monthly Notices of the Royal Astronomical Society, 1983. 202: p. 615-627.
- 38. Fasano, G. and A. Franceschini, A multidimensional version of the Kolmogorov-Smirnov test. Monthly Notices of the Royal Astronomical Society, 1987. 225: p. 155-170.
- 39. Witten, I. H. and E. Frank, Data Mining: Practical Machine Learning Tools and Techniques. Second ed. Morgan Kaufmann Series in Data Management Systems, ed. J. Gray. 2005, San Francisco, Calif.: Elsevier. 523.
- 40. Venables, W. N., B. D. Ripley, and W. N. Venables, Modern applied statistics with S. 4th ed. Statistics and computing. 2002, New York: Springer. xi, 495 p.
- 41. Switzer, R. C., III, S. K. Campbell, and L. Murdock, Histological analysis method. 1993: USA.
- 42. Uchihara, T., et al., Triple immunofluorolabeling with two rabbit polyclonal antibodies and a mouse monoclonal antibody allowing three-dimensional analysis of cotton wool plaques in Alzheimer disease. J Histochem Cytochem, 2003. 51(9): p. 1201-6.
- 43. Strategic analysis of the ADME/Tox technologies market in Europe. 2005, Frost and Sullivan.
- The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.
- While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (21)
1. A method for producing a cellular systems biology profile of one or more tissue samples comprising:
a) obtaining at least two sections from one or more tissue samples;
b) labeling at least one section with a histological stain, thereby producing a histologically stained section;
c) labeling at least one section with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled section, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
d) imaging the histologically stained section with at least a first optical mode, wherein the imaging produces a first set of data;
e) imaging the fluorescently labeled section with at least a second optical mode, wherein the imaging produces a second set of data;
f) analyzing the first set of data and the second set of data to identify five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data, and wherein the combination of the five or more features generates a cellular systems biology profile of the one or more tissue samples,
wherein at least the steps of e) and f) are automated, thereby providing a method for producing a cellular systems biology profile of the one or more tissue samples.
2. The method of claim 1 , wherein the method further comprises comparing the cellular systems biology profiles of two or more tissue samples, thereby identifying similarities, differences, or combinations thereof, of the two or more tissue samples.
3. The method of claim 1 , wherein two or more tissue samples are isolated from a human patient at one or more time points, wherein at least one tissue sample is isolated from each time point from the human patient.
4. The method of claim 1 , wherein the histological stain is selected from the group consisting of alcian blue, Fuchsin, haematoxylin and eosin (H&E), Masson trichrome, toluidine blue, Wright's/Giemsa stain, and combinations thereof.
5. The method of claim 1 , wherein the panel of fluorescently labeled reagents is selected from the group consisting of fluorescently labeled antibodies, fluorescently labeled peptides, fluorescently labeled proteins, fluorescently labeled aptamers, fluorescently labeled oligonucleotides, fluorescently labeled chemicals, fluorescent chemicals, and combinations thereof.
6. The method of claim 1 , wherein the panel of fluorescently labeled reagents indicate the presence, amount, location, activity, distribution, or combination thereof, of the biomarkers in the fluorescently labeled section.
7. The method of claim 1 , wherein the method further comprises comparing the reference cellular systems biology profile in the database with a cellular systems biology profile of one or more further samples, thereby identifying similarities, differences, or a combination thereof, of the cellular systems biology profile of the one or more further samples and the reference cellular systems biology profile.
8. The method of claim 7 , wherein the cellular systems biology profile of the one or more further samples and the cellular systems biology profile in the database are compared using one or more of a graphical display, cluster analysis, or statistical measure of correlation.
9. The method of claim 1 , further comprising producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples, comprising:
i) obtaining at least one blood sample smear from at least one peripheral blood sample;
ii) labeling the at least one blood sample smear with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
iii) imaging the fluorescently labeled blood sample smear with at least a third optical mode, wherein the imaging produces a third set of data;
iv) analyzing the third set of data to identify five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear,
thereby producing a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
10. The method of claim 1 , further comprising producing a cellular systems biology profile of one or more peripheral blood samples obtained from the same source as the one or more tissue samples, comprising:
i) obtaining at least two blood sample smears from one or more peripheral blood samples;
ii) labeling at least one blood sample smear with a histological stain, producing a histologically stained blood sample smear;
iii) labeling at least one blood sample smear with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
iv) imaging the histologically stained blood sample smear with at least a third optical mode, wherein the imaging produces a third set of data;
v) imaging the fluorescently labeled blood sample smear with at least a fourth optical mode, wherein the imaging produces a fourth set of data;
vi) analyzing the third set of data and the fourth set of data to identify five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, and wherein the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears,
thereby producing a cellular systems biology profile of the one or more peripheral blood samples obtained from the same source as the one or more tissue samples.
11. A method for producing a cellular systems biology profile of one or more tissue samples comprising:
a) obtaining at least one section from one or more tissue samples;
b) labeling the at least one section with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled section, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
c) imaging the fluorescently labeled section with at least a first optical mode, wherein the imaging produces a first set of data;
d) analyzing the first set of data to identify five or more features, wherein at least one feature is identified in the first set of data, and wherein the combination of the five or more features is a cellular systems biology profile the one or more tissue samples,
wherein at least the steps of e) and f) are automated, thereby providing a method for cellular systems biology profiling of the one or more tissue samples.
12. The method of claim 11 , further comprising producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples, comprising:
i) obtaining at least one blood sample smear from at least one peripheral blood sample;
ii) labeling the at least one blood sample smear with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
iii) imaging the fluorescently labeled blood sample smear with at least a second optical mode, wherein the imaging produces a second set of data;
iv) analyzing the second set of data to identify five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear,
thereby producing a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
13. The method of claim 11 , further comprising producing a cellular systems biology profile of one or more peripheral blood samples obtained from the same source as the one or more tissue samples, comprising:
i) obtaining at least two blood sample smears from one or more peripheral blood samples;
ii) labeling at least one blood sample smear with a histological stain, producing a histologically stained blood sample smear;
iii) labeling at least one blood sample smear with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
iv) imaging the histologically stained blood sample smear with at least a second optical mode, wherein the imaging produces a second set of data;
v) imaging the fluorescently labeled blood sample smear with at least a third optical mode, wherein the imaging produces a third set of data;
vi) analyzing the second set of data and the third set of data to identify five or more features, wherein at least one feature is identified in each of the second set of data and the third set of data, and wherein the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears,
thereby producing a cellular systems biology profile of the one or more peripheral blood samples obtained from the same source as the one or more tissue samples.
14. A method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer, or combination thereof, comprising:
a) obtaining at least two sections from one or more tissue samples, wherein the one or more tissue samples is selected from the group consisting a suspected cancerous tissue, a lymph node, and a combination thereof;
b) labeling at least one section with a histological stain, thereby producing a histologically stained section;
c) labeling at least one section with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled section, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents comprises fluorescently labeled reagents selected from the group consisting of:
i) a set of fluorescently labeled reagents specific for at least four cancer cell biomarkers;
ii) a set of fluorescently labeled reagents specific for at least four migratory immune cell biomarkers;
iii) a combination of:
A) a set of fluorescently labeled reagents specific for at least three cancer cell biomarkers; and
B) a set of fluorescently labeled reagents specific for at least three migratory immune cell biomarkers; and
iv) combinations thereof,
wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
d) imaging the histologically stained section with at least a first optical mode, wherein the imaging produces a first set of data;
e) imaging the fluorescently labeled section with at least a second optical mode, wherein the imaging produces a second set of data;
f) analyzing the first set of data and second set of data to identify five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data, and wherein the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples,
thereby providing a method for producing a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or combination thereof.
15. The method of claim 14 , further comprising producing a cellular systems biology profile of at least one peripheral blood sample obtained from the same source as the one or more tissue samples, comprising:
i) obtaining at least one blood sample smear from at least one peripheral blood sample;
ii) labeling the at least one blood sample smear with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
iii) imaging the fluorescently labeled blood sample smear with at least a third optical mode, wherein the imaging produces a third set of data;
iv) analyzing the third set of data to identify five or more features, wherein the five or more features is a cellular systems biology profile of the at least one blood sample smear,
thereby producing a cellular systems biology profile of the at least one peripheral blood sample obtained from the same source as the one or more tissue samples.
16. The method of claim 15 , wherein the at least one peripheral blood sample is taken at the same or different time point as the one or more tissue samples are obtained.
17. The method of claim 14 , further comprising producing a cellular systems biology profile of one or more peripheral blood samples obtained from the same source as the one or more tissue samples, wherein the tissue sample is profiled for presence of cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or a combination thereof, comprising:
a) obtaining at least two blood sample smears from one or more peripheral blood samples;
b) labeling at least one blood sample smear with a histological stain, thereby producing a histologically stained blood sample smear;
c) labeling at least one blood sample smear with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled blood sample smear, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
d) imaging the histologically stained blood sample smear with at least a third optical mode, wherein the imaging produces a third set of data;
e) imaging the fluorescently labeled blood sample smear with at least a fourth optical mode, wherein the imaging produces a fourth set of data;
f) analyzing the third set of data and the fourth set of data to identify five or more features, wherein at least one feature is identified in each of the third set of data and the fourth set of data, and wherein the combination of the five or more features is a cellular systems biology profile of the one or more blood sample smears,
thereby producing a cellular systems biology profile of one the or more peripheral blood samples obtained from the same source as the one or more tissue samples, wherein the tissue sample is profiled for the presence or absence of a cancer, the stage of a cancer, the diagnosis of a cancer, the prognosis of a cancer or a combination thereof.
18. The method of claim 17 , wherein the one or more peripheral blood samples are taken at the same or different time points as the one or more tissue samples are obtained.
19. The method of claim 14 , wherein at least the steps of d), e) and f) are automated.
20. A method for producing a cellular systems biology profile of one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity, comprising:
a) obtaining at least two sections from one or more tissue samples;
b) labeling at least one section with a histological stain, thereby producing a histologically stained section;
c) labeling at least one section with a panel of fluorescently labeled reagents, thereby producing a fluorescently labeled section, wherein each fluorescently labeled reagent is specific for a biomarker, and wherein the panel of fluorescently labeled reagents comprises a set of fluorescently labeled reagents selected from the group consisting of:
i) one or more fluorescently labeled reagents specific for cell metabolism biomarkers;
ii) one or more fluorescently labeled reagents specific for DNA damage biomarkers;
iii) one or more fluorescently labeled reagents specific for cell morphology biomarkers;
iv) one or more fluorescently labeled reagents specific for DNA damage biomarkers;
v) one or more fluorescently labeled reagents specific for cell differentiation biomarkers;
vi) one or more fluorescently labeled reagents specific for stress-induced transcription activation or inhibition biomarkers;
vii) one or more fluorescently labeled reagents specific for phosphorylation status of stress kinase biomarkers;
viii) one or more fluorescently labeled reagents specific for apoptosis or necrosis biomarkers;
ix) one or more fluorescently labeled reagents specific for cytoskeleton biomarkers;
x) one or more fluorescently labeled reagents specific for organelle biomarkers;
xi) one or more fluorescently labeled reagents specific for presence or activation of immune cell biomarkers; and
xii) combinations thereof,
wherein the panel of fluorescently labeled reagents detects at least four different biomarkers, and wherein the detection of a biomarker is a read-out of one or more features of a cellular systems biology profile;
d) imaging the histologically stained section with at least a first optical mode, wherein the imaging produces a first set of data;
e) imaging the fluorescently labeled section with at least a second optical mode, wherein the imaging produces a second set of data;
f) analyzing the first set of data and second set of data to identify five or more features, wherein at least one feature is identified in each of the first set of data and the second set of data, and wherein the combination of the five or more features is a cellular systems biology profile of the one or more tissue samples,
wherein at least the steps of d), e) and f) are automated, thereby providing a method for producing a cellular systems biology profile of the one or more tissue samples, wherein the tissue sample is profiled for the presence, severity or absence of a tissue toxicity.
21. The method of claim 20 , wherein the one or more tissue samples is one or more liver tissue samples.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/067,438 US20140212892A1 (en) | 2006-05-17 | 2013-10-30 | Method For Automated Tissue Analysis |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80103506P | 2006-05-17 | 2006-05-17 | |
PCT/US2007/011865 WO2007136724A2 (en) | 2006-05-17 | 2007-05-17 | Method for automated tissue analysis |
US22733409A | 2009-04-14 | 2009-04-14 | |
US201213346920A | 2012-01-10 | 2012-01-10 | |
US13/593,663 US8597899B2 (en) | 2006-05-17 | 2012-08-24 | Method for automated tissue analysis |
US14/067,438 US20140212892A1 (en) | 2006-05-17 | 2013-10-30 | Method For Automated Tissue Analysis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/593,663 Continuation US8597899B2 (en) | 2006-05-17 | 2012-08-24 | Method for automated tissue analysis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140212892A1 true US20140212892A1 (en) | 2014-07-31 |
Family
ID=38723843
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/227,334 Active 2028-12-10 US8114615B2 (en) | 2006-05-17 | 2007-05-17 | Method for automated tissue analysis |
US13/593,663 Active US8597899B2 (en) | 2006-05-17 | 2012-08-24 | Method for automated tissue analysis |
US14/067,438 Abandoned US20140212892A1 (en) | 2006-05-17 | 2013-10-30 | Method For Automated Tissue Analysis |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/227,334 Active 2028-12-10 US8114615B2 (en) | 2006-05-17 | 2007-05-17 | Method for automated tissue analysis |
US13/593,663 Active US8597899B2 (en) | 2006-05-17 | 2012-08-24 | Method for automated tissue analysis |
Country Status (6)
Country | Link |
---|---|
US (3) | US8114615B2 (en) |
EP (1) | EP2027465A2 (en) |
JP (2) | JP5406019B2 (en) |
CN (1) | CN101484806A (en) |
CA (1) | CA2652562C (en) |
WO (1) | WO2007136724A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180011000A1 (en) * | 2014-12-29 | 2018-01-11 | Flagship Biosciences, Inc. | Methods for quantitative assessment of muscle fibers in muscular dystrophy |
US10018631B2 (en) | 2011-03-17 | 2018-07-10 | Cernostics, Inc. | Systems and compositions for diagnosing Barrett's esophagus and methods of using the same |
WO2019147908A1 (en) * | 2018-01-26 | 2019-08-01 | Diagnostic Photonics, Inc. | Method and apparatus for classifying core biopsy specimens with optical coherence tomography |
WO2021167984A1 (en) * | 2020-02-17 | 2021-08-26 | 10X Genomics, Inc. | Systems and methods for machine learning features in biological samples |
WO2023091967A1 (en) * | 2021-11-16 | 2023-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for personalized treatment of tumors |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008507995A (en) * | 2004-08-02 | 2008-03-21 | セルーメン、インコーポレイテッド | Method for detecting molecular interactions in cells |
WO2008018905A2 (en) * | 2006-01-17 | 2008-02-14 | Cellumen, Inc. | Method for predicting biological systems responses |
JP5406019B2 (en) * | 2006-05-17 | 2014-02-05 | セルーメン、インコーポレイテッド | Method for automated tissue analysis |
US20100009352A1 (en) * | 2006-05-24 | 2010-01-14 | Gough Albert H | Method for Modeling a Disease |
US8060348B2 (en) * | 2006-08-07 | 2011-11-15 | General Electric Company | Systems for analyzing tissue samples |
US8131476B2 (en) | 2006-08-07 | 2012-03-06 | General Electric Company | System and method for co-registering multi-channel images of a tissue micro array |
EP2199956A1 (en) * | 2008-12-18 | 2010-06-23 | Siemens Aktiengesellschaft | Method and system for managing results of an analysis process on objects handled along a technical process line |
US20110231103A1 (en) * | 2010-03-19 | 2011-09-22 | Ye Fang | Methods for determining molecular pharmacology using label-free integrative pharmacology |
US20120264110A1 (en) * | 2011-04-12 | 2012-10-18 | Wachman Elliot S | Automated pap screening using a plurality of biomarkers and multi-spectral imaging |
US20120271553A1 (en) * | 2011-04-22 | 2012-10-25 | Ge Global Research | Analyzing the expression of biomarkers in cells with clusters |
US8831327B2 (en) * | 2011-08-30 | 2014-09-09 | General Electric Company | Systems and methods for tissue classification using attributes of a biomarker enhanced tissue network (BETN) |
EP2764468A4 (en) * | 2011-10-05 | 2015-11-18 | Cireca Theranostics Llc | Method and system for analyzing biological specimens by spectral imaging |
WO2013071099A1 (en) * | 2011-11-11 | 2013-05-16 | Cold Spring Harbor Laboratory, An Education Corporation Of The State Of New York | A drug screening method and uses thereof |
US8568991B2 (en) | 2011-12-23 | 2013-10-29 | General Electric Company | Photoactivated chemical bleaching of dyes |
US9176032B2 (en) | 2011-12-23 | 2015-11-03 | General Electric Company | Methods of analyzing an H and E stained biological sample |
US8416240B1 (en) * | 2012-04-02 | 2013-04-09 | Google Inc. | Determining 3D model information from stored images |
US9036888B2 (en) | 2012-04-30 | 2015-05-19 | General Electric Company | Systems and methods for performing quality review scoring of biomarkers and image analysis methods for biological tissue |
US8737709B2 (en) | 2012-04-30 | 2014-05-27 | General Electric Company | Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue |
US9798918B2 (en) * | 2012-10-05 | 2017-10-24 | Cireca Theranostics, Llc | Method and system for analyzing biological specimens by spectral imaging |
CN103105324B (en) * | 2013-01-29 | 2015-08-26 | 福州迈新生物技术开发有限公司 | A kind of method of same tangent plane Mutiple Targets protein immunization group or immunofluorescence label |
US9488639B2 (en) * | 2013-02-25 | 2016-11-08 | Flagship Biosciences, Inc. | Cell-based tissue analysis |
EP2965087B1 (en) | 2013-03-06 | 2018-10-17 | General Electric Company | Methods of analyzing an h&e stained biological sample |
US9372143B2 (en) * | 2013-05-15 | 2016-06-21 | Captl Llc | Scanning image flow cytometer |
CN104250302B (en) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | The anti-antibody of PD 1 and its application |
DK3063291T3 (en) * | 2013-10-11 | 2019-05-06 | Ventana Med Syst Inc | MULTIPLEX HER2 AND ESTROGEN RECEPTOR CO-COLORING ASSAYS TO DETECT TUMOR HOROGENETIC |
US9308296B2 (en) | 2014-05-05 | 2016-04-12 | Warsaw Orthopedic, Inc. | Tissue processing apparatus and method |
US20160160169A1 (en) * | 2014-12-03 | 2016-06-09 | IsoPlexis Corporation | Analysis and screening of poly-functional secretion profiles |
US10900885B2 (en) | 2014-12-19 | 2021-01-26 | Captl Llc | Flow cytometry using hydrodynamically planar flow |
JP6670757B2 (en) * | 2014-12-26 | 2020-03-25 | 国立大学法人 東京大学 | Judgment device, analysis method, and analysis program |
US20180040120A1 (en) * | 2014-12-29 | 2018-02-08 | Flagship Biosciences, Inc. | Methods for quantitative assessment of mononuclear cells in muscle tissue sections |
US10036698B2 (en) | 2015-06-19 | 2018-07-31 | Captl Llc | Time-sequential cytometry |
CN104990781B (en) * | 2015-06-29 | 2018-02-16 | 中国医学科学院皮肤病研究所 | The melanocyte SABC haematoxylin-dual staining counter of toluidine blue |
CA3006356A1 (en) | 2015-11-25 | 2017-06-01 | Cernostics, Inc. | Methods of predicting progression of barrett's esophagus |
US10786298B2 (en) | 2016-03-01 | 2020-09-29 | Covidien Lp | Surgical instruments and systems incorporating machine learning based tissue identification and methods thereof |
CA2956230C (en) * | 2016-04-29 | 2020-01-14 | Synaptive Medical (Barbados) Inc. | Multi-modal optical imaging system for tissue analysis |
US10568567B1 (en) * | 2016-05-31 | 2020-02-25 | Vium, Inc | Method of drug approval using motion vector analysis |
US10913930B2 (en) | 2016-08-09 | 2021-02-09 | Warsaw Orthopedic, Inc. | Tissue processing apparatus and method for infusing bioactive agents into tissue |
WO2018063914A1 (en) | 2016-09-29 | 2018-04-05 | Animantis, Llc | Methods and apparatus for assessing immune system activity and therapeutic efficacy |
CA2954115C (en) * | 2016-10-16 | 2022-04-12 | Neil Gordon | Ultra-sensitive bioanalyte quantification from self-assembled quadruplex tags |
JP7356904B2 (en) | 2016-10-27 | 2023-10-05 | コーニンクレッカ フィリップス エヌ ヴェ | Apparatus for determining cellular composition information in one or more tissue samples |
CN110431637A (en) * | 2017-02-09 | 2019-11-08 | 莱维特医疗公司 | System and method for tissue samples processing |
CA3068084C (en) * | 2017-09-09 | 2023-11-28 | Neil Gordon | Bioanalyte signal amplification and detection with artificial intelligence diagnosis |
WO2019169157A1 (en) * | 2018-02-28 | 2019-09-06 | Visiongate, Inc. | Morphometric detection of malignancy associated change |
EP3761031A4 (en) | 2018-02-28 | 2022-06-01 | Nitto Boseki Co., Ltd. | Method for isolating cell nuclei having enhanced antigenicity from immobilized cells or ffpe tissue section, and antigen activator and kit therefor |
FR3079617B1 (en) * | 2018-03-29 | 2023-12-22 | Office National Detude Et De Rech Aerospatiales Onera | METHOD FOR DETECTING CELLS PRESENTING AT LEAST ONE ANOMALY IN A CYTOLOGICAL SAMPLE |
HK1257467A2 (en) * | 2018-06-22 | 2019-10-18 | Master Dynamic Ltd | Cancer cell detection and imaging system, process and product |
DE102018005064A1 (en) * | 2018-06-26 | 2020-01-02 | Hans-Ulrich Dodt | 3D pathology procedures |
CN113376386A (en) * | 2020-03-09 | 2021-09-10 | 中国科学院广州生物医药与健康研究院 | Marker for viral pneumonia and application thereof |
CN111539354B (en) * | 2020-04-27 | 2020-12-15 | 易普森智慧健康科技(深圳)有限公司 | Liquid-based cytology slide scanning area identification method |
CN112051250B (en) * | 2020-09-09 | 2021-11-23 | 南京诺源医疗器械有限公司 | Medical fluorescence imaging image light supplement adjusting system and adjusting method |
CN113390666B (en) * | 2021-06-17 | 2023-01-24 | 安徽科丞智能健康科技有限责任公司 | Method for detecting performance index of chemical substance in cell |
JP7283642B1 (en) | 2021-09-29 | 2023-05-30 | 日東紡績株式会社 | Methods for Enrichment of Cells or Cell Nuclei |
CN113935983A (en) * | 2021-10-28 | 2022-01-14 | 北京中科与点科技中心(有限合伙) | Full-automatic quantitative analysis method for perinuclear lysosome distribution |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114615B2 (en) * | 2006-05-17 | 2012-02-14 | Cernostics, Inc. | Method for automated tissue analysis |
Family Cites Families (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047321A (en) | 1988-06-15 | 1991-09-10 | Becton Dickinson & Co. | Method for analysis of cellular components of a fluid |
US5733721A (en) | 1992-11-20 | 1998-03-31 | The Board Of Regents Of The University Of Oklahoma | Cell analysis method using quantitative fluorescence image analysis |
US5995645A (en) | 1993-08-18 | 1999-11-30 | Applied Spectral Imaging Ltd. | Method of cancer cell detection |
FI101829B (en) | 1995-03-07 | 1998-08-31 | Erkki Juhani Soini | Biospecific assay method |
ATE184613T1 (en) | 1995-09-22 | 1999-10-15 | Novo Nordisk As | VARIANTS OF GREEN FLUORESCENCE PROTEIN, GFP |
AU7398996A (en) | 1995-10-11 | 1997-04-30 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US5981180A (en) | 1995-10-11 | 1999-11-09 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US5989835A (en) | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
EP0912892B1 (en) | 1996-05-30 | 2008-09-17 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US20060141539A1 (en) | 1996-05-30 | 2006-06-29 | Taylor D L | Miniaturized cell array methods and apparatus for cell-based screening |
US6103479A (en) | 1996-05-30 | 2000-08-15 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
DE19634873A1 (en) | 1996-08-29 | 1998-03-12 | Boehringer Mannheim Gmbh | System for the differentiation of fluorescent groups of molecules by time-resolved fluorescence measurement |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US7306914B2 (en) | 1997-01-31 | 2007-12-11 | Odyssey Thera Inc. | Protein fragment complementation assays in whole animals applications to drug efficacy, ADME, cancer biology, immunology, infectious disease and gene therapy |
US6897017B1 (en) | 1997-01-31 | 2005-05-24 | Odyssey Thera Inc. | Vivo library-versus-library selection of optimized protein-protein interactions |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US7062219B2 (en) | 1997-01-31 | 2006-06-13 | Odyssey Thera Inc. | Protein fragment complementation assays for high-throughput and high-content screening |
US5885840A (en) | 1997-02-10 | 1999-03-23 | Compucyte Corp. | Multiple assays of cell specimens |
US6416959B1 (en) | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
US6759206B1 (en) | 1997-02-27 | 2004-07-06 | Cellomics, Inc. | System for cell-based screening |
US7853411B2 (en) | 1997-02-27 | 2010-12-14 | Cellomics, Inc. | System for cell-based screening |
DK0983498T3 (en) | 1997-02-27 | 2004-08-16 | Cellomics Inc | Cell-based screening system |
US6727071B1 (en) | 1997-02-27 | 2004-04-27 | Cellomics, Inc. | System for cell-based screening |
US6756207B1 (en) | 1997-02-27 | 2004-06-29 | Cellomics, Inc. | System for cell-based screening |
US7117098B1 (en) | 1997-02-27 | 2006-10-03 | Cellomics, Inc. | Machine-readable storage medium for analyzing distribution of macromolecules between the cell membrane and the cell cytoplasm |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
EP1199564B1 (en) | 1997-04-07 | 2004-06-23 | BioImage A/S | A method for screening substances for effect on intracellular translocation |
US6259807B1 (en) | 1997-05-14 | 2001-07-10 | Applied Imaging Corp. | Identification of objects of interest using multiple illumination schemes and finding overlap of features in corresponding multiple images |
US7160687B1 (en) | 1997-05-29 | 2007-01-09 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US6548263B1 (en) | 1997-05-29 | 2003-04-15 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US5876946A (en) | 1997-06-03 | 1999-03-02 | Pharmacopeia, Inc. | High-throughput assay |
CA2277414A1 (en) | 1997-11-07 | 1999-05-20 | Georges Natsoulis | Surrogate genetics target characterization method |
AU2322099A (en) | 1998-01-16 | 1999-08-02 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US7166424B2 (en) | 1998-02-02 | 2007-01-23 | Odyssey Thera Inc. | Fragments of fluorescent proteins for protein fragment complementation assays |
US20050221280A1 (en) | 1998-02-02 | 2005-10-06 | Odyssey Thera, Inc. | Protein-protein interactions for pharmacological profiling |
US7282350B2 (en) | 1998-02-12 | 2007-10-16 | Immunivest Corporation | Labeled cell sets for use as functional controls in rare cell detection assays |
ES2272057T3 (en) | 1998-02-25 | 2007-04-16 | The United States Government As Represented By The Department Of Health And Human Services | METHOD AND APPARATUS FOR MAKING A PROVISION FOR THE FAST DETERMINATION OF MOLECULAR PROFILES. |
US6242205B1 (en) | 1998-04-24 | 2001-06-05 | Yale University | Method of detecting drug-receptor and protein-protein interactions |
US5965352A (en) | 1998-05-08 | 1999-10-12 | Rosetta Inpharmatics, Inc. | Methods for identifying pathways of drug action |
US6324479B1 (en) | 1998-05-08 | 2001-11-27 | Rosetta Impharmatics, Inc. | Methods of determining protein activity levels using gene expression profiles |
US6218122B1 (en) | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
EP1095277B1 (en) | 1998-07-13 | 2003-01-22 | Cellomics, Inc. | A system for cell-based screening |
AU6048599A (en) | 1998-09-18 | 2000-04-10 | Cellomics, Inc. | A system for cell-based screening |
AU752677B2 (en) | 1998-09-22 | 2002-09-26 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US6146830A (en) | 1998-09-23 | 2000-11-14 | Rosetta Inpharmatics, Inc. | Method for determining the presence of a number of primary targets of a drug |
AU5790199A (en) | 1998-10-05 | 2000-04-26 | Duke University | Method and apparatus for detecting binding interactions (in vivo) |
US6203987B1 (en) | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
US6950752B1 (en) | 1998-10-27 | 2005-09-27 | Rosetta Inpharmatics Llc | Methods for removing artifact from biological profiles |
ATE225406T1 (en) | 1998-10-30 | 2002-10-15 | Cellomics Inc | A CELL-BASED SCREENING SYSTEM |
US6453241B1 (en) | 1998-12-23 | 2002-09-17 | Rosetta Inpharmatics, Inc. | Method and system for analyzing biological response signal data |
CA2356891A1 (en) | 1998-12-23 | 2000-07-06 | Rosetta Inpharmatics, Inc. | Methods for robust discrimination of profiles |
US6801859B1 (en) | 1998-12-23 | 2004-10-05 | Rosetta Inpharmatics Llc | Methods of characterizing drug activities using consensus profiles |
US6222093B1 (en) | 1998-12-28 | 2001-04-24 | Rosetta Inpharmatics, Inc. | Methods for determining therapeutic index from gene expression profiles |
US6370478B1 (en) | 1998-12-28 | 2002-04-09 | Rosetta Inpharmatics, Inc. | Methods for drug interaction prediction using biological response profiles |
IL144797A0 (en) | 1999-02-26 | 2002-06-30 | Cellomics Inc | A system for cell-based screening |
JP2002541458A (en) | 1999-04-01 | 2002-12-03 | セロミックス インコーポレイテッド | Miniaturized cell array method and apparatus for cell-based screening |
US20030228565A1 (en) | 2000-04-26 | 2003-12-11 | Cytokinetics, Inc. | Method and apparatus for predictive cellular bioinformatics |
WO2000070528A2 (en) | 1999-05-14 | 2000-11-23 | Cytokinetics, Inc. | Method and apparatus for predictive cellular bioinformatics |
EP1185863A2 (en) | 1999-05-14 | 2002-03-13 | Cellomics, Inc. | Optical system analysis of cells |
WO2000079241A2 (en) | 1999-06-21 | 2000-12-28 | Cellomics, Inc. | A system for cell-based screening |
EP1196774A2 (en) | 1999-07-27 | 2002-04-17 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
AU6366200A (en) | 1999-07-27 | 2001-02-13 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US6986993B1 (en) | 1999-08-05 | 2006-01-17 | Cellomics, Inc. | System for cell-based screening |
AU6622800A (en) | 1999-08-05 | 2001-03-05 | Cellomics, Inc. | A system for cell-based screening |
IL147793A0 (en) | 1999-08-05 | 2002-08-14 | Cellomics Inc | Optical system analysis of cells |
ATE412184T1 (en) | 1999-08-17 | 2008-11-15 | Luminex Corp | METHOD FOR ANALYZING A PLURALITY OF SAMPLES OF DIFFERENT ORIGINS FOR ONE ANALYTE |
US6753413B1 (en) | 1999-08-30 | 2004-06-22 | The Hong Kong University Of Science & Technology | P35NCK5A binding proteins |
WO2001020533A2 (en) | 1999-09-15 | 2001-03-22 | Luminex Corporation | Creation of a database of biochemical data and methods of use |
US6312956B1 (en) | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
AU1465801A (en) | 1999-11-03 | 2001-05-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis |
WO2001035072A2 (en) | 1999-11-09 | 2001-05-17 | Cellomics, Inc. | A system for cell-based screening |
WO2001042786A2 (en) | 1999-12-09 | 2001-06-14 | Cellomics, Inc. | System for cell based screening : cell spreading |
AU4007401A (en) | 2000-03-06 | 2001-09-17 | Bioseek Inc | Function homology screening |
US7266458B2 (en) | 2000-03-06 | 2007-09-04 | Bioseek, Inc. | BioMAP analysis |
US6763307B2 (en) | 2000-03-06 | 2004-07-13 | Bioseek, Inc. | Patient classification |
JP2001327296A (en) | 2000-03-15 | 2001-11-27 | Japan Science & Technology Corp | Method for detecting interaction between protein and protein |
AU2001261499A1 (en) | 2000-05-12 | 2001-11-26 | Yale University | Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins |
CA2414626A1 (en) | 2000-07-04 | 2002-01-10 | Bioimage A/S | A method for extracting quantitative information relating to interactions between cellular components |
CA2417233A1 (en) | 2000-08-29 | 2002-03-07 | Yeda Research & Development Co. Ltd. | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
AU2001294872A1 (en) | 2000-09-28 | 2002-04-08 | Cellomics, Inc. | Methods and reagents for live-cell gene expression quantification |
EP1328880A4 (en) | 2000-10-12 | 2004-12-15 | Iconix Pharm Inc | Interactive correlation of compound information and genomic information |
US20020102614A1 (en) | 2000-11-17 | 2002-08-01 | Davis Roger J. | Use of ZPR1 as a molecular probe for spinal muscular atrophy |
US6599694B2 (en) | 2000-12-18 | 2003-07-29 | Cytokinetics, Inc. | Method of characterizing potential therapeutics by determining cell-cell interactions |
WO2002052272A2 (en) | 2000-12-23 | 2002-07-04 | Evotec Oai Ag | Technique and screening method for detecting reversible protein-protein interactions |
US7016787B2 (en) | 2001-02-20 | 2006-03-21 | Cytokinetics, Inc. | Characterizing biological stimuli by response curves |
US6956961B2 (en) | 2001-02-20 | 2005-10-18 | Cytokinetics, Inc. | Extracting shape information contained in cell images |
EP1368653B1 (en) | 2001-03-12 | 2013-01-23 | Cellomics, Inc. | Methods to increase the capacity of high content cell-based screening assays |
WO2002077903A2 (en) | 2001-03-26 | 2002-10-03 | Cellomics, Inc. | Methods for determining the organization of a cellular component of interest |
AU2002256347A1 (en) | 2001-04-20 | 2002-11-05 | President And Fellows Of Harvard College | Compositions and methods for the identification of protein interactions in vertebrate cells |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
US20030044847A1 (en) | 2001-05-15 | 2003-03-06 | Sidney Pestka | Methods for anlyzing interactions between proteins in live and intact cells |
US8000949B2 (en) | 2001-06-18 | 2011-08-16 | Genego, Inc. | Methods for identification of novel protein drug targets and biomarkers utilizing functional networks |
AU2002337664B2 (en) | 2001-08-01 | 2007-01-25 | Cellomics, Inc. | Novel fusion proteins and assays for molecular binding |
AU2002365911A1 (en) | 2001-08-06 | 2003-09-04 | Vanderbilt University | System and methods for discriminating an agent |
DE10143757A1 (en) | 2001-09-06 | 2003-03-27 | Werner M | In situ determination of tissue characteristics, useful e.g. for diagnosis of tumors, by using specific detection agents that are transiently labeled |
US20030096016A1 (en) * | 2001-09-07 | 2003-05-22 | Yeda Research And Development Co. Ltd. | Methods of kidney transplantation utilizing developing nephric tissue |
US20040043436A1 (en) | 2001-09-21 | 2004-03-04 | Antonia Vlahou | Biomarkers of transitional cell carcinoma of the bladder |
GB0123352D0 (en) | 2001-09-28 | 2001-11-21 | Koninkl Philips Electronics Nv | Image display |
CA2462598A1 (en) | 2001-10-01 | 2003-04-10 | Bioimage A/S | A method of detecting intracellular protein-protein interactions using three heterologous conjugates |
DE10211653A1 (en) | 2002-03-15 | 2003-10-02 | Klaus Pfizenmaier | Filament recruitment of fluorescent proteins for analysis and identification of protein-protein interactions: FIT (Filament-based Interaction Trap) analysis |
US7274809B2 (en) | 2002-08-29 | 2007-09-25 | Perceptronix Medical, Inc. And British Columbia Cancer Agency | Computerized methods and systems related to the detection of malignancy-associated changes (MAC) to detect cancer |
US7865534B2 (en) | 2002-09-30 | 2011-01-04 | Genstruct, Inc. | System, method and apparatus for assembling and mining life science data |
US20050059153A1 (en) | 2003-01-22 | 2005-03-17 | George Frank R. | Electromagnetic activation of gene expression and cell growth |
US7691580B2 (en) | 2003-01-29 | 2010-04-06 | Corning Incorporated | Reverse protein delivery into cells on coded microparticles |
ATE489452T1 (en) | 2003-02-27 | 2010-12-15 | Veridex Llc | CIRCULATING TUMOR CELLS (CTC'S): EARLY ASSESSMENT OF TIME-TO-PROGRESSION, SURVIVAL AND RESPONSE TO THERAPY IN PATIENTS WITH METASTATIC CANCER |
EP1620722A4 (en) | 2003-04-23 | 2008-01-30 | Bioseek Inc | Methods for characterizing signaling pathways and compounds that interact therewith |
EP1625394A4 (en) | 2003-04-23 | 2008-02-06 | Bioseek Inc | Methods for analysis of biological dataset profiles |
US7235353B2 (en) | 2003-07-18 | 2007-06-26 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
US20050014217A1 (en) | 2003-07-18 | 2005-01-20 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
US7461048B2 (en) | 2003-07-21 | 2008-12-02 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
US7483554B2 (en) | 2003-11-17 | 2009-01-27 | Aureon Laboratories, Inc. | Pathological tissue mapping |
US7505948B2 (en) | 2003-11-18 | 2009-03-17 | Aureon Laboratories, Inc. | Support vector regression for censored data |
WO2005023987A2 (en) | 2003-09-03 | 2005-03-17 | Bioseek, Inc. | Cell-based assays for determining drug action |
US7269517B2 (en) | 2003-09-05 | 2007-09-11 | Rosetta Inpharmatics Llc | Computer systems and methods for analyzing experiment design |
US20050136509A1 (en) | 2003-09-10 | 2005-06-23 | Bioimagene, Inc. | Method and system for quantitatively analyzing biological samples |
US20050136549A1 (en) | 2003-10-30 | 2005-06-23 | Bioimagene, Inc. | Method and system for automatically determining diagnostic saliency of digital images |
US7760927B2 (en) | 2003-09-10 | 2010-07-20 | Bioimagene, Inc. | Method and system for digital image based tissue independent simultaneous nucleus cytoplasm and membrane quantitation |
WO2005048823A2 (en) | 2003-11-17 | 2005-06-02 | Janssen Pharmaceutica N.V. | Modeling of systemic inflammatory response to infection |
CA2546869A1 (en) | 2003-11-26 | 2005-06-16 | Genstruct, Inc. | System, method and apparatus for causal implication analysis in biological networks |
US20050154535A1 (en) | 2004-01-09 | 2005-07-14 | Genstruct, Inc. | Method, system and apparatus for assembling and using biological knowledge |
WO2005075669A1 (en) | 2004-02-09 | 2005-08-18 | Universität Bonn | Reverse transcription based method for detecting gene expression in a cell |
CN1922490B (en) | 2004-02-19 | 2012-07-04 | 耶鲁大学 | Identification of cancer protein biomarkers using proteomic techniques |
JP2007527239A (en) | 2004-02-27 | 2007-09-27 | バイオシーク インコーポレイティッド | Biological data set profiling method for asthma and atopy |
WO2005091203A2 (en) | 2004-03-12 | 2005-09-29 | Aureon Laboratories, Inc. | Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition |
EP1756577B1 (en) | 2004-03-24 | 2012-03-14 | Tripath Imaging, Inc. | Methods and compositions for the detection of cervical disease |
ES2527426T3 (en) | 2004-05-07 | 2015-01-23 | Cepheid | Combined detection of biological agents |
JP2005323573A (en) * | 2004-05-17 | 2005-11-24 | Sumitomo Pharmaceut Co Ltd | Method for analyzing gene expression data and, method for screening disease marker gene and its utilization |
CA2573112A1 (en) | 2004-07-09 | 2006-01-26 | Tripath Imaging, Inc. | Methods and compositions for the detection of ovarian cancer |
JP2008507995A (en) | 2004-08-02 | 2008-03-21 | セルーメン、インコーポレイテッド | Method for detecting molecular interactions in cells |
CA2575859A1 (en) | 2004-08-11 | 2006-02-23 | Aureon Laboratories, Inc. | Systems and methods for automated diagnosis and grading of tissue images |
US20060040338A1 (en) | 2004-08-18 | 2006-02-23 | Odyssey Thera, Inc. | Pharmacological profiling of drugs with cell-based assays |
ATE520988T1 (en) | 2004-09-22 | 2011-09-15 | Tripath Imaging Inc | METHODS AND COMPOSITIONS FOR EVALUATION OF BREAST CANCER PROGNOSIS |
US20060094059A1 (en) | 2004-09-22 | 2006-05-04 | Odyssey Thera, Inc. | Methods for identifying new drug leads and new therapeutic uses for known drugs |
US20060160109A1 (en) | 2004-11-22 | 2006-07-20 | Odyssey Thera, Inc. | Harnessing network biology to improve drug discovery |
US20060159325A1 (en) | 2005-01-18 | 2006-07-20 | Trestle Corporation | System and method for review in studies including toxicity and risk assessment studies |
CA2596640A1 (en) | 2005-02-04 | 2006-08-10 | Rosetta Inpharmatics Llc | Methods of predicting chemotherapy responsiveness in breast cancer patients |
US9734282B2 (en) | 2005-03-28 | 2017-08-15 | Discoverx Corporation | Biological dataset profiling of cardiovascular disease and cardiovascular inflammation |
US7767395B2 (en) | 2005-04-15 | 2010-08-03 | Becton, Dickinson And Company | Diagnosis of sepsis |
US20070019854A1 (en) | 2005-05-10 | 2007-01-25 | Bioimagene, Inc. | Method and system for automated digital image analysis of prostrate neoplasms using morphologic patterns |
US7410763B2 (en) | 2005-09-01 | 2008-08-12 | Intel Corporation | Multiplex data collection and analysis in bioanalyte detection |
WO2007038792A2 (en) | 2005-09-28 | 2007-04-05 | H. Lee Moffitt Cancer Center | Individualized cancer treatments |
US8093012B2 (en) | 2005-10-13 | 2012-01-10 | Aureon Laboratories, Inc. | Multiplex in situ immunohistochemical analysis |
US7599893B2 (en) | 2005-10-13 | 2009-10-06 | Aureon Laboratories, Inc. | Methods and systems for feature selection in machine learning based on feature contribution and model fitness |
GB2433986A (en) | 2006-01-09 | 2007-07-11 | Cytokinetics Inc | Granularity analysis in cellular phenotypes |
WO2007080583A2 (en) | 2006-01-10 | 2007-07-19 | Applied Spectral Imaging Ltd. | Methods and systems for analyzing biological samples |
GB2434225A (en) | 2006-01-13 | 2007-07-18 | Cytokinetics Inc | Random forest modelling of cellular phenotypes |
WO2008018905A2 (en) | 2006-01-17 | 2008-02-14 | Cellumen, Inc. | Method for predicting biological systems responses |
US20070212721A1 (en) | 2006-01-27 | 2007-09-13 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
US7790463B2 (en) | 2006-02-02 | 2010-09-07 | Yale University | Methods of determining whether a pregnant woman is at risk of developing preeclampsia |
ATE535612T1 (en) | 2006-03-06 | 2011-12-15 | Ceetox Inc | TOXICITY SCREENING PROCEDURES |
GB2435925A (en) | 2006-03-09 | 2007-09-12 | Cytokinetics Inc | Cellular predictive models for toxicities |
WO2007103535A2 (en) | 2006-03-09 | 2007-09-13 | Cytokinetics, Inc. | Cellular predictive models for toxicities |
WO2007103492A2 (en) | 2006-03-09 | 2007-09-13 | Cytokinetics, Inc. | Cellular predictive models for toxicities |
WO2007103531A2 (en) | 2006-03-09 | 2007-09-13 | Cytokinetics, Inc. | Cellular predictive models for toxicities |
GB2435923A (en) | 2006-03-09 | 2007-09-12 | Cytokinetics Inc | Cellular predictive models for toxicities |
US20070225956A1 (en) | 2006-03-27 | 2007-09-27 | Dexter Roydon Pratt | Causal analysis in complex biological systems |
JP5048757B2 (en) | 2006-05-05 | 2012-10-17 | イェール・ユニバーシティー | Use of subcellular localization profiles as diagnostic or predictive indicators |
US20100009352A1 (en) | 2006-05-24 | 2010-01-14 | Gough Albert H | Method for Modeling a Disease |
US7706591B2 (en) | 2006-07-13 | 2010-04-27 | Cellomics, Inc. | Neuronal profiling |
CA2657324A1 (en) | 2006-07-13 | 2008-01-17 | Yale University | Methods for making cancer prognoses based on subcellular localization of biomarkers |
US7811778B2 (en) | 2006-09-06 | 2010-10-12 | Vanderbilt University | Methods of screening for gastrointestinal cancer |
WO2008060483A2 (en) | 2006-11-10 | 2008-05-22 | Cellumen, Inc. | Protein-protein interaction biosensors and methods of use thereof |
WO2008115420A2 (en) | 2007-03-15 | 2008-09-25 | Cellumen, Inc. | Methods for detecting molecular interactions within cells using combination of inducible promoters and biosensors |
WO2009002565A1 (en) | 2007-06-26 | 2008-12-31 | Cellumen, Inc. | Method for predicting biological systems responses in hepatocytes |
-
2007
- 2007-05-17 JP JP2009511073A patent/JP5406019B2/en active Active
- 2007-05-17 WO PCT/US2007/011865 patent/WO2007136724A2/en active Application Filing
- 2007-05-17 CA CA2652562A patent/CA2652562C/en active Active
- 2007-05-17 EP EP07777137A patent/EP2027465A2/en not_active Ceased
- 2007-05-17 US US12/227,334 patent/US8114615B2/en active Active
- 2007-05-17 CN CNA2007800248147A patent/CN101484806A/en active Pending
-
2012
- 2012-08-24 US US13/593,663 patent/US8597899B2/en active Active
-
2013
- 2013-10-30 US US14/067,438 patent/US20140212892A1/en not_active Abandoned
- 2013-10-31 JP JP2013226607A patent/JP5888521B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8114615B2 (en) * | 2006-05-17 | 2012-02-14 | Cernostics, Inc. | Method for automated tissue analysis |
US8597899B2 (en) * | 2006-05-17 | 2013-12-03 | Cernostics, Inc. | Method for automated tissue analysis |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10018631B2 (en) | 2011-03-17 | 2018-07-10 | Cernostics, Inc. | Systems and compositions for diagnosing Barrett's esophagus and methods of using the same |
US20180011000A1 (en) * | 2014-12-29 | 2018-01-11 | Flagship Biosciences, Inc. | Methods for quantitative assessment of muscle fibers in muscular dystrophy |
WO2019147908A1 (en) * | 2018-01-26 | 2019-08-01 | Diagnostic Photonics, Inc. | Method and apparatus for classifying core biopsy specimens with optical coherence tomography |
US11226189B2 (en) | 2018-01-26 | 2022-01-18 | Diagnostic Photonics, Inc. | Method and apparatus for classifying core biopsy specimens with optical coherence tomography |
WO2021167984A1 (en) * | 2020-02-17 | 2021-08-26 | 10X Genomics, Inc. | Systems and methods for machine learning features in biological samples |
WO2023091967A1 (en) * | 2021-11-16 | 2023-05-25 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for personalized treatment of tumors |
Also Published As
Publication number | Publication date |
---|---|
EP2027465A2 (en) | 2009-02-25 |
JP2014029346A (en) | 2014-02-13 |
US20130190198A1 (en) | 2013-07-25 |
CA2652562C (en) | 2015-05-12 |
JP5888521B2 (en) | 2016-03-22 |
JP2009537822A (en) | 2009-10-29 |
JP5406019B2 (en) | 2014-02-05 |
CA2652562A1 (en) | 2007-11-29 |
WO2007136724A3 (en) | 2008-03-13 |
CN101484806A (en) | 2009-07-15 |
US20090298703A1 (en) | 2009-12-03 |
WO2007136724A2 (en) | 2007-11-29 |
US8597899B2 (en) | 2013-12-03 |
US8114615B2 (en) | 2012-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8597899B2 (en) | Method for automated tissue analysis | |
Bodenmiller | Multiplexed epitope-based tissue imaging for discovery and healthcare applications | |
Levsky et al. | Fluorescence in situ hybridization: past, present and future | |
Gough et al. | Biologically relevant heterogeneity: metrics and practical insights | |
Colin et al. | Quantitative 3D-imaging for cell biology and ecology of environmental microbial eukaryotes | |
Valet et al. | Cytomics—new technologies: towards a human cytome project | |
US20090170091A1 (en) | Method For Predicting Biological Systems Responses | |
EP2171443A1 (en) | Method for predicting biological systems responses in hepatocytes | |
CN110494739A (en) | The determination of fluorescent image target density | |
Bouzekri et al. | Multidimensional profiling of drug‐treated cells by imaging mass cytometry | |
Kwok et al. | Multiplexed laser particles for spatially resolved single-cell analysis | |
Levenson et al. | Modern Trends in Imaging X: Spectral Imaging in Preclinical Research and Clinical Pathology | |
Haney | High content screening: science, techniques and applications | |
Levenson et al. | Multispectral imaging and pathology: seeing and doing more | |
Tárnok | Slide‐based cytometry for cytomics—A minireview | |
Pierzchalski et al. | Introduction A: Recent advances in cytometry instrumentation, probes, and methods | |
Kolmar et al. | Technological and computational advances driving high-throughput oncology | |
Chong et al. | Proteome-wide screens in Saccharomyces cerevisiae using the yeast GFP collection | |
Tárnok et al. | Cytomics–importance of multimodal analysis of cell function and proliferation in oncology | |
Mignardi et al. | Bridging histology and bioinformatics—computational analysis of spatially resolved transcriptomics | |
Lin et al. | A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours | |
Gambe et al. | Development of a multistage classifier for a monitoring system of cell activity based on imaging of chromosomal dynamics | |
EP4109333A1 (en) | Method for analysing biological samples | |
WO2009015263A2 (en) | Methods for characterizing cell proximity | |
Conroy et al. | Developing a Comprehensive Taxonomy for Human Cell Types |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELLUMEN, INC, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOUGH, ALBERT H.;GIULIANO, KENNETH A.;TAYLOR, D. LANSING;REEL/FRAME:031832/0105 Effective date: 20060601 Owner name: CERNOSTICS, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELLUMEN, INC.;REEL/FRAME:031832/0254 Effective date: 20100525 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |